Professor Stephen Clarke

OAM
Professor of Medicine
Medicine, Northern Clinical School
Kolling Institute of Medical Research

Telephone +61 2 9926 5048 / 7494
Fax +61 2 9767 7603

Map

Research interests

Cancer pharmacology, colorectal cancer, lung cancer

International links

China

(Renji Hospital and Shanghai Jiaotong University) Clinical trial of ethnic differences in tolerability of chemotherapy

Selected grants

2014

  • Northern Translational Cancer Research Centre; Engel A, Bailey D, Boyle F, Clarke S, Gill A, Marsh D, Molloy M; Cancer Institute New South Wales/Translational Cancer Research Centre.

2013

  • Advance care planning in incurable cancer patients with disease progression on first line chemotherapy: a randomised trial; Clarke S; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Towards Personalizing Chemotherapeutic Treatment for Cancer - Investigating Inter-Ethnic Differences in Genetic Susceptibility to Anti-Cancer Drug Toxicity; Howell V, Clarke S; Rebecca L Cooper Medical Research Foundation/Equipment Grant.
  • Advance care planning in incurable cancer patients with disease progression on first line chemotherapy: a randomised trial.; Tattersall M, Silvester W, Clayton J, Detering K, Hall J, Butow P, Kiely B, Cebon J, Clarke S, Bell M; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • The impact of physical activity on fatigue and quality of life in lung cancer patients; Vardy J, Clarke S, Dhillon H, Boyer M; Slater and Gordon Asbestos Research Fund/Vojakovic Fellowship.
  • MALDI MS Imaging for Cancer Biomarker Discovery in the Northern Translational Cancer Research Unit; Clarke S; NSW Cancer Institute/Research Infrastructure Grant.
  • Ginkgo biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind, placebo-controlled, randomised phase III trial; Tattersall M, Vardy J, Dhillon H, Bell M, Cysique L, Boyle F, Clarke S; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Bruker Daltonics autoflex speed MALDI-TOF/TOF mass spectrometer; Baxter R, Halliday G, Marsh D, Gill A, Clarke S, Smith R, Little C, Jackson C, O'Neill C, Murphy C, Sharland A, Chadban S, Mason R, Assinder S, Verdurand M, Richardson D, Machaalani R, Hambly B, Chan-Ling T, Dos Remedios C, Holsinger D, Lay P; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Determining the tumour suppressor function of the MCC gene and its significance to treatment outcomes in colorectal cancer; Clarke S; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Bruker Daltonics autoflex speed MALDI-TOF/TOF mass spectrometer, with associated Biomarker Identification and MALDI-Imaging Solutions; Clarke S; University of Sydney/Cancer Research Fund.
  • Bruker Daltonics autoflex speed MALDI-TOF/TOF mass spectrometer, with associated Biomarker Identification and MALDI-Imaging solutions; Clarke S; University of Sydney/Cancer Research Fund Research Infrastructure Grant.
  • Ginkgo biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind, placebo-controlled, randomised phase III trial; Clarke S; Cancer Australia/Research.

2011

  • Northern Translational Cancer Research Unit; Engel A, Clarke S; Cancer Institute New South Wales/Translational Health Services Research Grant.
  • Northern Translational Cancer Research Unit; Clarke S; NSW Cancer Institute/Translational Cancer Research Unit Establishment Grant.
  • Identifying New Plasma Markers In Mesothelioma; Clarke S; NSW Cancer Institute/Research Innovation Grant.
  • Genotype Guided Cancer Therapy (Genomic Theranostics); Clarke S; Cancer Council New South Wales/Strategic Research Partnership (STREP) Grants.

2010

  • GenomeLab GeXP Genetic Analysis System for the Multi-Disciplinary Sydney Cancer Gene Expression Facility; Richardson D, Halliday G, Scolyer R, Clarke S, Lee C, Reichardt J, Clarke C, Murray M, Boyer M, Kefford R; Cancer Institute New South Wales/Equipment Grant.
  • The Lunar PIXImus II DEXA Scanner; Zhou H, Seibel M, Handelsman D, Le Couteur D, Nicholson G, Clarke S, Robertson G, van Zandwijk N, Freedman B, Kennerson M, Allan C, Walters K, Cogger V, Blair I, Reid G, Simanainen U; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Improving the use of chemotherapy by targeting the inflammatory response; Clarke S, Robertson G, Piquette-Miller M, McLachlan A, Baker M, Katsifis A; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Genomelab GeXP Genetic Analysis System for the Multi-Disciplinary Sydney Cancer Gene Expression Facility; Clarke S; NSW Cancer Institute/Research Equipment Grant.
  • Building capacity in pharmacogenomics across NSW: PRIMe (Pharmacogenomic Research for Individualised Medicine); Clarke S; Cancer Council New South Wales/Research Program Grant in Cancer Pharmacogenomics.
  • A mass spectrometer for cancer biomarker research; Clarke S; NSW Cancer Institute/Research Equipment Grant.
  • A proteomic approach to identify predictive biomarkers of molecular targeted drugs; Charles (nee Slaviero) K, Clarke S; Cancer Institute New South Wales/Research Innovation Grants.

2009

  • Clinical Studies of the Efficacy and Tolerability of Systemically Administered Complementary and Alternative Medicine (CAM) in Conjunction with Standary Therapy in Cancer Patients; Vardy J, Clarke S; National Center for Complementary Medicine /Integrated Care Research Program.
  • China: NSW Cancer Genesis, Spread and Treatment Proteomic Discovery Program; Baker M, Wilkins M, Hancock W, Malloy M, Clarke S, Wilkins M, Packer N, He F; Office for Science and Medical Research (NSW)/China - NSW Collaborative Research Grant Program.
  • The impact of physical activity on quality of life in thoracic cancer patients; Clarke S; Lance Armstrong Foundation/Young Investigator Grant.
  • -80°C Scientific freezer for storage of blood samples; Clarke S; Sydney Cancer Centre Foundation/Capital Works & Equipment Grant.
  • Predictors of Cancer Drug Metabolism; Clarke S; University of Sydney/Bridging Support.
  • China:NSW Cancer Genesis, Spread, & Treatment Proteomic Discovery Program; Clarke S; NSW Office for Science and Medical Research /The China-NSW Collaborative Research Program.
  • Individualised treatment for cancer patients: Impact of tumour-derived cytokines on drug clearance pathways in cancer; Clarke S; DVC Research/Bridging Support Grant.
  • Multi-photon microscope for intravital imaging; Weninger W, Vadas M, Hogg P, Norris M, Fazekas B, Haass N, Clarke S, Halliday G, Rasko J, Holst J, McCaughan G, Allen J, Gamble J, Dong Q, Byrne S, Richardson D; Cancer Institute New South Wales/Equipment Grant.
  • Inverted Multiphoton Intravital Microscope; Weninger W, Gorrell M, Halliday G, Jones C, Fazekas B, Richardson D, Clarke S, Gamble J, Bertolino P, Vadas M, Dong Q, Rasko J, Holst J, McCaughan G, Byrne S, Saunders B, Triccas J, Haass N; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • The impact of physical activity on quality of life in thoracic cancer patients; Vardy J, Dhillon H, Van Der Ploeg H, Clarke S, Boyer M, Bauman A; Lance Armstrong Foundation/Young Investigator Grant.
  • Clinical studies of the efficacy & tolerability of systemically administered Complementary & Alternative Medicine (CAM) in conjunction with standard therapy in cancer patients; Clarke S; National Institute of Complementary Medicine /Research Program Developmental Grant.

2008

  • Inter-Ethnic Differences in Tolerance of Anti-Cancer drugs; Clarke S, McLachlan A; National Health and Medical Research Council (NHMRC)/Project Grants.

2007

  • Use of Proteomic Analyses to improve the management of colorectal cancer - the SCRIPT for CRC Projec; Chan C, Kohonen-Corish M, Robertson G, Clarke S, Baker M, Beale P, Christopherson R, Bokey E, Horvath L, Lin B, Hong A, Solomon M, Chapuis P, McKay M, Mark M; Cancer Institute New South Wales/Translational Program Grant.
  • Cognitive Function and Fatigue in cancer patients after chemotherapy; Vardy J, Clarke S, Tannock I, Schnitzler M, Dhillon H; National Health and Medical Research Council (NHMRC)/Project Grants.

2005

  • A randomised phase II trial of single agent irinotecan versus irinotecan plus De Gramont schedule 5- fluorouroacil and folinic acid, plus or minus celecoxib in patients with previously treated metastatic colorectal cancer (De Vinci); Clarke S, Leaney N, Conley R, Clarke S; Pfizer Australia Pty Ltd through AGITG/BLO Project.
  • Repression of hepatic drug metabolism by solid tumours; Robertson G, Clarke S, Polly P, Liddle C; National Health and Medical Research Council (NHMRC)/Project Grants.
  • ProteomeX MS and personnel support for the new facuility; Baxter R, Christopherson R, Daly R, Guilhaus M, Kavallaris M, Clarke S, Molloy M, Baker M; Cancer Institute New South Wales/Research Support.

2004

  • Impact of human cytochrome P450 3A allelic variants on the toxicity of docetaxel and irinotecan; Clarke S, Ramzan I, Murray M; University of Sydney/Cancer Research Fund.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Clarke, S., McLachlan, A. (2012). Interaction Between Complementary and Alternative Medicines and Conventional Medicines. In Olver, I and Robotin, M (Eds.), Perspectives on Complementary and Alternative Medicines, (pp. 227-259). London: Imperial College Press.
  • Van Der Wall, H., Elison, B., Frater, C., Bruce, W., Clarke, S. (2012). Pathophysiology of Bone Metastases. In Ignac Fogelman, Gopinath Gnanasegaran, Hans Van der Wall. (Eds.), Radionuclide and Hybrid Bone Imaging, (pp. 59-84). Heidelberg: Springer.
  • Fung, D., Lo, A., Jankova, L., Clarke, S., Molloy, M., Robertson, G., Wilkins, M. (2011). Classification of Cancer Patients Using Pathway Analysis and Network Clustering. In Gerard Cagney, Andrew Emili (Eds.), Network Biology: Methods and Applications, (pp. 311-336). New York: Humana Press.
  • Clarke, S. (2011). Successes, challenges and future directions. In Dimitrios H Roukos (Eds.), Advances in Personalized Cancer Management, (pp. 84-95). London: Future Medicine Ltd.
  • Clarke, S., McLachlan, A., Brown, D., Carbonara, S., Kissane, R. (2010). Beyond Conventional Cancer Treatments: The Use of Complementary Therapies During Cancer Treatment: Implications for Clinicians. In Monica Robotin, Ian Olver and Afaf Girgis (Eds.), When Cancer Crosses Disciplines: A Physician's Handbook, (pp. 285-315). London: Imperial College Press.
  • Read, J., Clarke, S. (2008). Clinical Nutrition. In E. Bruera, I. Higginson, C. Ripamonti, C. von Gunten (Eds.), Palliative Medicine, (pp. 595-601). United Kingdom: Hodder Arnold.
  • Van Der Wall, H., Clarke, S., Murray, I. (2003). Evaluation of primary bone tumours. In Peter J. Ell & Sanjiv Sam Gambhir (Eds.), Nuclear Medicine in Clinical Diagnosis and Treatment. 3rd ed, (pp. 623-639). Edinburgh: Churchill Livingstone.
  • Van Der Wall, H., Clarke, S., Murray, I. (2003). The evaluation of malignancy: metastatic bone disease. In Peter J. Ell & Sanjiv Sam Gambhir (Eds.), Nuclear Medicine in Clinical Diagnosis and Treatment. 3rd ed, (pp. 641-655). Edinburgh: Churchill Livingstone.

Journals

  • Wang, F., Gill, A., Neale, M., Puttaswamy, V., Gananadha, S., Pavlakis, N., Clarke, S., Hugh, T., Samra, J. (2014). Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 21(6), 1937-1947. [More Information]
  • Chik, J., Zhou, J., Moh, E., Christopherson, R., Clarke, S., Molloy, M., Packer, N. (2014). Comprehensive glycomics comparison between colon cancer cell cultures and tumours: Implications for biomarker studies. International Journal of Proteomics, 108(C), 146-162. [More Information]
  • Tsoli, M., Schweiger, M., Vanniasinghe, A., Painter, A., Zechner, R., Clarke, S., Robertson, G. (2014). Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation. PLoS One, 9(3), e92966- 1-e92966- 12. [More Information]
  • Hayes, S., Hudson, A., Clarke, S., Molloy, M., Howell, V. (2014). From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell & Developmental Biology, 27, 118-127. [More Information]
  • Kohonen-Corish, M., Tseung, J., Chan, C., Currey, N., Dent, O., Clarke, S., Chapuis, P. (2014). KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. International Journal of Cancer, 134, 2820-2828. [More Information]
  • Hibbert, E., Lambert, T., Carter, J., Learoyd, D., Twigg, S., Clarke, S. (2013). A randomized controlled pilot trial comparing the impact of access to clinical endocrinology video demonstrations with access to usual revision resources on medical student performance of clinical endocrinology skills. BMC Medical Education, 13(1), 1-10. [More Information]
  • Clarke, S., Burge, M., Cordwell, C., Gibbs, P., Reece, W., Tebbutt, N. (2013). An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (AvastinTM) [ASCENT]. BMC Cancer, 13, 1-7. [More Information]
  • Toon, C., Walsh, M., Chou, A., Capper, D., Clarkson, A., Sioson, L., Clarke, S., Mead, S., Walters, R., Clendenning, M., Gill, A., et al (2013). BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. American Journal of Surgical Pathology, 37(10), 1592-1602. [More Information]
  • Elens, L., Nieuweboer, A., Clarke, S., Charles (nee Slaviero), K., De Graan, A., Haufroid, V., Mathijssen, R., Van Schaik, R. (2013). CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics, 14(2), 137-149. [More Information]
  • Kao, S., Lee, K., Klebe, S., Henderson, D., McCaughan, B., Vardy, J., Clarke, S., van Zandwijk, N. (2013). Excision Repair Cross Complementation Group 1 and Thymidylate Synthase Expression in Patients With Mesothelioma. Clinical Lung Cancer, 14(2), 164-171. [More Information]
  • Kacevska, M., Mahns, A., Sharma, R., Clarke, S., Robertson, G., Liddle, C. (2013). Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling. Pharmaceutical Research, 30(9), 2270-2278. [More Information]
  • Linton, A., Pond, G., Clarke, S., Vardy, J., Galsky, M., Sonpavde, G. (2013). Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy. Clinical Genitourinary Cancer, 11(4), 423-430. [More Information]
  • Kao, S., Vardy, J., Harvie, R., Chatfield, M., van Zandwijk, N., Clarke, S., Pavlakis, N. (2013). Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Supportive Care in Cancer, 21(3), 697-705. [More Information]
  • Linton, A., Kao, S., Vardy, J., Clarke, S., van Zandwijk, N., Klebe, S. (2013). Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review. Asia-Pacific Journal of Clinical Oncology, 9(3), 273-279. [More Information]
  • Elens, L., Nieuweboer, A., Clarke, S., Charles (nee Slaviero), K., De Graan, A., Haufroid, V., van Gelder, T., Mathijssen, R., Van Schaik, R. (2013). Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and Genomics, 23(3), 148-155. [More Information]
  • Vardy, J., Dhillon, H., Clarke, S., Olesen, I., Leslie, F., Warby, A., Beith, J., Sullivan, A., Hamilton, A., Beale, P., Rittau, A., McLachlan, A. (2013). Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. SpringerPlus, 2(1), 1-5. [More Information]
  • Clarke, S., Karapetis, C., Gibbs, P., Pavlakis, N., Desai, J., Michael, M., Tebbutt, N., Price, T., Tabernero, J. (2013). Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. Critical Reviews in Oncology / Hematology (online), 85(2), 121-135. [More Information]
  • Kao, S., Clarke, S., Vardy, J., Corte, P., Clarke, C., van Zandwijk, N. (2013). Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. Internal Medicine Journal, 43(4), 402-410. [More Information]
  • Jankova, L., Dent, O., Chan, C., Chapuis, P., Clarke, S. (2013). Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer-specific survival after curative resection of node-positive colorectal cancer. BMC Cancer, 13, 1-13. [More Information]
  • Stein, R., Sharpe, L., Bell, M., Boyle, F., Dunn, S., Clarke, S. (2013). Randomized Controlled Trial of a Structured Intervention to Facilitate End-of-Life Decision Making in Patients With Advanced Cancer. Journal of Clinical Oncology, 31(27), 3403-3410. [More Information]
  • Hasovits, C., Pavlakis, N., Howell, V., Gill, A., Clarke, S. (2013). Resistance to EGFR targeted antibodies - expansion of clones present from the start of treatment. The more things change, the more they stay the same (Plus ca change, plus ca ne change pas!). Translational Gastrointestinal Cancer, 28(1), 44-46. [More Information]
  • Guthrie, G., Charles (nee Slaviero), K., Roxburgh, C., Horgan, P., McMillan, D., Clarke, S. (2013). The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Critical Reviews in Oncology / Hematology (online), 88(1), 218-230. [More Information]
  • Findlay, M., Bauer, J., Clarke, S., Isenring, E. (2013). Understanding nutritional issues in the older person with cancer. Cancer Forum, 37(3), 234-237.
  • Kao, S., van Zandwijk, N., Corte, P., Clarke, C., Clarke, S., Vardy, J. (2013). Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. Supportive Care in Cancer, 21(7), 1879-1884. [More Information]
  • Kao, S., Vardy, J., Chatfield, M., Corte, P., Pavlakis, N., Clarke, C., van Zandwijk, N., Clarke, S. (2013). Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board. Clinical Lung Cancer, 14(1), 70-77. [More Information]
  • de Marinis, F., Clarke, S. (2013). Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer. Lung Cancer, 82(3), 511-511. [More Information]
  • Oh, B., Butow, P., Mullan, B., Hale, A., Lee, M., Guo, X., Clarke, S. (2012). A Critical Review of the Effects of Medical Qigong on Quality of Life, Immune Function, and Survival in Cancer Patients. Integrative Cancer Therapies, 11(2), 101-110. [More Information]
  • Proctor, M., McMillan, D., Morrison, D., Fletcher, C., Horgan, P., Clarke, S. (2012). A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. British Journal of Cancer, 107(4), 695-699. [More Information]
  • Michael, M., Pavlakis, N., Clingan, P., de Boer, R., Johnston, M., Clarke, S. (2012). A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. Oncology reports, 28(3), 763-767. [More Information]
  • Tsoli, M., Moore, M., Burg, D., Painter, A., Taylor, R., Lockie, S., Turner, N., Warren, A., Cooney, G., Oldfield, B., Clarke, S., et al (2012). Activation of Thermogenesis in Brown Adipose Tissue and Dysregulated Lipid Metabolism Associated with Cancer Cachexia in Mice. Cancer Research, 72(17), 4372-4382. [More Information]
  • De Gramont, A., Van Cutsem, E., Schmoll, H., Tabernero, J., Clarke, S., Moore, M., Cunningham, D., Cartwright, T., Hecht, J., Rivera, F., et al (2012). Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncology, 13(12), 1225-1233. [More Information]
  • Bullen, T., Sharpe, L., Lawsin, C., Patel (nee Chauhan), D., Clarke, S., Bokey, E. (2012). Body image as a predictor of psychopathology in surgical patients with colorectal disease. Journal of Psychosomatic Research, 73(6), 459-463. [More Information]
  • Davis, E., Oh, B., Butow, P., Mullan, B., Clarke, S. (2012). Cancer Patient Disclosure and Patient-Doctor Communication of Complementary and Alternative Medicine Use: A Systematic Review. The Oncologist, 17(11), 1475-1481. [More Information]
  • Shum, A., Mahendradatta, T., Taylor, R., Painter, A., Moore, M., Tsoli, M., Tan, T., Clarke, S., Robertson, G., Polly, P. (2012). Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging, 4(2), 133-143. [More Information]
  • Michael, M., Cullinane, C., Hatzimihalis, A., O'Kane, C., Milner, A., Booth, R., Schlicht, S., Clarke, S., Francis, P. (2012). Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. Cancer Chemotherapy and Pharmacology, 69(1), 125-135. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Lee, M., Rosenthal, D., Larkey, L., Vardy, J. (2012). Effect of Medical Qigong on Cognitive function, Quality of Life and a Biomarker of Inflammation in Cancer Patients: A Randomized Controlled Trial. Supportive Care in Cancer, 20(6), 1235-1242. [More Information]
  • Jankova, L., Robertson, G., Chan, C., Tan, K., Kohonen-Corish, M., Fung, C., Clarke, C., Lin, B., Molloy, M., Chapuis, P., Bokey, E., Dent, O., Clarke, S. (2012). Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study. BMC Cancer, 12, 1-9. [More Information]
  • Kho, P., Jankova, L., Fung, C., Chan, C., Clarke, C., Lin, B., Robertson, G., Molloy, M., Chapuis, P., Bokey, E., Dent, O., Clarke, S. (2012). Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front. International Journal of Colorectal Disease: clinical and molecular gastroenterology and surgery, 27(11), 1409-1417. [More Information]
  • Hasovits, C., Clarke, S. (2012). Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics. Clinical Pharmacokinetics, 51(4), 203-224. [More Information]
  • Randall, S., McKay, M., Pascovici, D., Mahon, K., Horvath, L., Clarke, S., Molloy, M. (2012). Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. Proteomics - Clinical Applications, 6(11-12), 626-634. [More Information]
  • Chua, W., Horvath, L., Beale, P., Clarke, S. (2012). Reporting clinical trial information: colorectal cancer trials at Sydney Cancer Centre. Internal Medicine Journal, 42(4), 416-421. [More Information]
  • Chellappa, K., Jankova, L., Schnabl, J., Pan, S., Brelivet, Y., Fung, C., Chan, C., Dent, O., Clarke, S., Robertson, G., et al (2012). Src tyrosine kinase phosphorylation of nuclear receptor HNF4a correlates with isoform-specific loss of HNF4a in human colon cancer. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 109(7), 2302-2307. [More Information]
  • Chua, W., Clarke, S., Charles (nee Slaviero), K. (2012). Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Supportive Care in Cancer, 20(8), 1869-1874. [More Information]
  • Clarey, J., Kao, S., Clarke, S., Vardy, J. (2012). The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials. Annals of Oncology, 23(5), 1229-1233. [More Information]
  • Dhillon, H., Van Der Ploeg, H., Bell, M., Boyer, M., Clarke, S., Vardy, J. (2012). The impact of physical activity on fatigue and quality of life in lung cancer patients: A randomised controlled trial protocol. BMC Cancer, 12, 1-9. [More Information]
  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012). The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer, 75(2), 248-254. [More Information]
  • Linton, A., Vardy, J., Clarke, S., van Zandwijk, N. (2012). The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma. Critical Reviews in Oncology / Hematology (online), 84(2), 200-212. [More Information]
  • Kho, P., Chapuis, P., Beale, P., Bokey, E., Dent, O., Clarke, S. (2012). Use of adjuvant chemotherapy in stage C (III) rectal cancer: Comparison of data from matched patients in a teaching hospital's clinico-pathological database. Asia-Pacific Journal of Clinical Oncology, 8(4), 346-355. [More Information]
  • Kao, S., Yan, T., Lee, K., Burn, J., Henderson, D., Klebe, S., Kennedy, C., Vardy, J., Clarke, S., Van Zandwijk, N., et al (2011). Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. Journal of Thoracic Oncology, 6(3), 602-605. [More Information]
  • Phan, V., Tan, C., Rittau, A., Xu, H., McLachlan, A., Clarke, S. (2011). An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 7(11), 1395-1410. [More Information]
  • He, X., Clarke, S., McLachlan, A. (2011). Clinical pharmacology of chemotherapy agents in older people with cancer. Current Gerontology and Geriatrics Research, 2011, 628670-1-628670-6. [More Information]
  • Chua, W., Kho, P., Moore, M., Charles (nee Slaviero), K., Clarke, S. (2011). Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Critical Reviews in Oncology / Hematology, 79(3), 224-250. [More Information]
  • Tan, K., Jankova, L., Chan, C., Fung, C., Clarke, C., Lin, B., Robertson, G., Molloy, M., Chapuis, P., Bokey, E., Clarke, S., et al (2011). Clinicopathological correlates and prognostic significance of glutathione S-transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer. Histopathology, 59(6), 1057-1070. [More Information]
  • Zhou, J., Belov, L., Solomon, M., Chan, C., Clarke, S., Christopherson, R. (2011). Colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing. Journal of Visualized Experiments, (55), 1-6. [More Information]
  • Kacevska, M., Downes, M., Sharma, R., Evans, R., Clarke, S., Liddle, C., Robertson, G. (2011). Extrahepatic Cancer Suppresses Nuclear Receptor–Regulated Drug Metabolism. Clinical Cancer Research, 17(10), 3170-3180. [More Information]
  • Clarke, S., McLachlan, A. (2011). Interaction between complementary and alternative medicine with conventional anti-cancer medicine. Cancer Forum, 35(1), 18-23.
  • Lee, A., Chick, J., Kolarich, D., Haynes, P., Robertson, G., Tsoli, M., Jankova, L., Clarke, S., Packer, N., Baker, M. (2011). Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumour. Molecular and Cellular Proteomics, 10(9), 1-18. [More Information]
  • Kao, S., Klebe, S., Henderson, D., Reid, G., Chatfield, M., Armstrong, N., Yan, T., Vardy, J., Clarke, S., van Zandwijk, N., McCaughan, B. (2011). Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy. Journal of Thoracic Oncology, 6(11), 1923-1929. [More Information]
  • Chua, W., Charles (nee Slaviero), K., Baracos, V., Clarke, S. (2011). Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. British Journal of Cancer, 104(8), 1288-1295. [More Information]
  • Backshall, A., Sharma, R., Clarke, S., Keun, H. (2011). Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clinical Cancer Research, 17(9), 3019-3028. [More Information]
  • Jankova, L., Chan, C., Fung, C., Song, X., Kwun, S., Cowley, M., Kaplan, W., Dent, O., Bokey, E., Chapuis, P., Robertson, G., Clarke, S., et al (2011). Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Molecular BioSystems, 7(11), 2997-3005. [More Information]
  • Mitchell, P., Broad, A., Rosenthal, M., Galettis, P., Abraham, R., Burns, I., Clarke, S., Milner, A., Diiulio, J., Links, M. (2011). Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 7(4), 376-384. [More Information]
  • Oh, B., Hu, G., Kao, S., Gebski, V., Walls, R., Truong, L., Beale, P., Clarke, S. (2011). Safety and tolerability of Chinese Herbal Medicine with cancer patients receiving chemotherapy. WebmedCentral, 2(Article ID: WMC001671), 1-11.
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Goldstein, D., Horvath, L., Tattersall, M., et al (2011). Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of Clinical Oncology, 29(15), 2077-2084. [More Information]
  • Sharpe, L., Patel (nee Chauhan), D., Clarke, S. (2011). The relationship between body image disturbance and distress in colorectal cancer patients with and without stomas. Journal of Psychosomatic Research, 70(5), 395-402. [More Information]
  • Clarke, S., Chua, W., Moore, M., Kao, S., Phan, V., Tan, C., Charles (nee Slaviero), K., McMillan, D. (2011). Use of inflammatory markers to guide cancer treatment. Clinical Pharmacology and Therapeutics, 90(3), 475-478. [More Information]
  • Patel (nee Chauhan), D., Sharpe, L., Thewes, B., Bell, M., Clarke, S. (2011). Using the distress thermometer and hospital anxiety and depression scale to screen for psychosocial morbidity in patients diagnosed with colorectal cancer. Journal of Affective Disorders, 131(1-3), 412-416. [More Information]
  • Kao, S., Griggs, K., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Burn, J., McCaughan, B., Henderson, D., et al (2011). Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology, 43(4), 313-317. [More Information]
  • Kao, S., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Reid, G., Burn, J., McCaughan, B., Henderson, D., et al (2011). Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology, 43(2), 128-132. [More Information]
  • Cassidy, J., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Rittweger, K., Gilberg, F., Saltz, L. (2011). XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. British Journal of Cancer, 105(1 Spring 2010), 58-64. [More Information]
  • Blinman, P., Duric, V., Nowak, A., Beale, P., Clarke, S., Briscoe, K., Boyce, A., Goldstein, D., Hudson, M., Stockler, M. (2010). Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile? European Journal of Cancer, 46(10), 1800-1807. [More Information]
  • Chua, W., Clarke, S. (2010). Clinical Trial Information As a Measure of Quality Cancer Care. Journal of Oncology Practice, 6(3), 170-171. [More Information]
  • Fung, C., Chan, C., Jankova, L., Dent, O., Robertson, G., Molloy, M., Bokey, E., Chapuis, P., Lin, B., Clarke, S. (2010). Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer. Histopathology, 56(3), 319-330. [More Information]
  • Chan, C., Jankova, L., Fung, C., Clarke, C., Robertson, G., Chapuis, P., Bokey, E., Lin, B., Dent, O., Clarke, S. (2010). Fascin Expression Predicts Survival After Potentially Curative Resection of Node-positive Colon Cancer. American Journal of Surgical Pathology, 34(5), 656-666. [More Information]
  • Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research, 16(23), 5805-5813. [More Information]
  • Lam, F., Jankova, L., Dent, O., Molloy, M., Kwun, S., Clarke, C., Chapuis, P., Robertson, G., Beale, P., Clarke, S., Bokey, E., Chan, C. (2010). Identification of distinctive protein expression patterns in colorectal adenoma. Proteomics - Clinical Applications, 4(1), 60-70. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Kothe, E., Lam, L., Rosenthal, D. (2010). Impact of Medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. Annals of Oncology, 21(3), 608-614. [More Information]
  • Moore, M., Chua, W., Charles (nee Slaviero), K., Clarke, S. (2010). Inflammation and Cancer: Causes and Consequences. Clinical Pharmacology and Therapeutics, 87(4), 504-508. [More Information]
  • Kho, P., Chua, W., Moore, M., Clarke, S. (2010). Is it Prime Time for Personalized Medicine in Cancer Treatment? Personalized Medicine, 7(4), 387-397.
  • Kao, S., Reid, G., Lee, K., Vardy, J., Clarke, S., van Zandwijk, N. (2010). Malignant Mesothelioma. International Medical Journal. [More Information]
  • Kao, S., Butow, P., Bray, V., Clarke, S., Vardy, J. (2010). Patient and oncologist estimates of survival in advanced cancer patients. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 10(2), 213-218.
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010). Patient-Doctor Communication: Use of Complementary and Alternative Medicine by Adult Patients with Cancer. Journal of the Society for Integrative Oncology, 8(2), 56-64. [More Information]
  • Kao, S., Phan, V., Clarke, S. (2010). Predictive Markers for Haematological Toxicity of Pemetrexed. Current Drug Targets, 11(1), 48-57. [More Information]
  • Zhou, J., Belov, L., Huang, P., Shin, J., Solomon, M., Chapuis, P., Bokey, E., Chan, C., Clarke, C., Clarke, S., Christopherson, R. (2010). Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. Journal of Immunological Methods, 355(40210 (1-2)), 40-51. [More Information]
  • Matic, M., Carradin, A., Tsoli, M., Clarke, S., Polly, P., Robertson, G. (2010). The alternatively spliced murine pregnane X receptor isoform, mPXRΔ171–211 exhibits a repressive action. The International Journal of Biochemistry and Cell Biology, 42(5), 672-682. [More Information]
  • Oh, B., Butow, P., Mullan, B., Beale, P., Pavlakis, N., Rosenthal, D., Clarke, S. (2010). The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. Asia-Pacific Journal of Clinical Oncology, 6(4), 342-349. [More Information]
  • Matic, M., Nakhel, S., Lehnert, A., Polly, P., Clarke, S., Robertson, G. (2009). A novel approach to investigate the subcellular distribution of nuclear receptors in vivo. Nuclear Receptor Signaling, 7(-), 1-7. [More Information]
  • Chapuis, P., Bokey, E., Clarke, S., Beale, P., Dent, O. (2009). Adjuvant chemotherapy for stage C colonic cancer in a multidisciplinary setting. ANZ Journal of Surgery, 79(10), 685-692. [More Information]
  • Chua, W., Peters, M., Loneragan, R., Clarke, S. (2009). Cetuximab-Associated Pulmonary Toxicity. Clinical Colorectal Cancer, 8(2), 118-120. [More Information]
  • Vardy, J., Dadasovich, R., Beale, P., Boyer, M., Clarke, S. (2009). Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC Cancer, 9(Article number 130), 130-1-130-6. [More Information]
  • Hong, P., Moore, M., McLachlan, A., Piquette-Miller, M., Xu, H., Clarke, S. (2009). Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opinion on Drug Metabolism and Toxicology, 5(3), 243-257. [More Information]
  • Sharma, R., Cunningham, D., Smith, P., Robertson, G., Dent, O., Clarke, S. (2009). Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients-analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. BMC Cancer, 9, 153-1-153-10. [More Information]
  • Chua, W., Goldstein, D., Lee, C., Dhillon, H., Michael, M., Mitchell, P., Clark, S., Iacopetta, B. (2009). Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 101(6), 998-1004. [More Information]
  • Sobrero, A., Ackland, S., Clarke, S., Perez-Carrion, R., Chiara, S., Gapski, J., Mainwaring, P., Langer, B., Young, S. (2009). Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer. Oncology, 77(2), 113-119.
  • Chua, W., Moore, M., Charles (nee Slaviero), K., Clarke, S. (2009). Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Current Opinion in Molecular Therapeutics, 11(6), 611-622. [More Information]
  • Chua, W., Moore, M., Beale, P., Clarke, S. (2009). Third-line Treatment Options for Metastatic Colorectal Cancer. Asia Pacific Journal of Oncology and Hematology, 1(1), 27-35.
  • Van Cutsem, E., Verslype, C., Beale, P., Clarke, S., Bugat, R., Rakhit, A., Fettner, S., Brennscheidt, U., Feyereislova, A., Delord, J. (2008). A phase lb dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Annals of Oncology, 19(2), 332-339. [More Information]
  • Saltz, L., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T., Rivera, F., et al (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of Clinical Oncology, 26(12), 2013-2019. [More Information]
  • Sharma, R., Kacevska, M., London, R., Clarke, S., Liddle, C., Robertson, G. (2008). Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. British Journal of Cancer, 98(1), 91-97. [More Information]
  • Robertson, G., Liddle, C., Clarke, S. (2008). Inflammation and Altered Drug Clearance in Cancer: Transcriptional Repression of a Human CYP3A4 Transgene in Tumor-bearing Mice. Pharmacology and Therapeutics, 83(6), 894-897. [More Information]
  • Kacevska, M., Robertson, G., Clarke, S., Liddle, C. (2008). Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opinion on Drug Metabolism and Toxicology, 4(2), 137-149. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S. (2008). Medical Qigong for cancer patients: Pilot study of impact on quality of life, side effects of treatment and inflammation. American Journal of Chinese Medicine, 36(3), 459-472. [More Information]
  • Harrison, J., Solomon, M., Young, J., Meagher, A., Butow, P., Salkeld, G., Hruby, G., Clarke, S. (2008). Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. JAMA (formerly Archives Of Surgery), 143(4), 389-394. [More Information]
  • Haller, D., Cassidy, J., Clarke, S., Cunningham, D., Hoff, P., Rothenberg, M., Saltz, L., Allegra, C., et al (2008). Potential regional differences for the tolerability profiles of fluoropyrimidines. Journal of Clinical Oncology, 26(13), 2118-2123. [More Information]
  • Cassidy, J., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T., Rivera, F., et al (2008). Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Journal of Clinical Oncology, 26(12), 2006-2012. [More Information]
  • Morgan, E., Goralski, K., Piquette-Miller, M., Renton, K., Robertson, G., Chaluvadi, M., Charles, K., Clarke, S., Kacevska, M., Liddle, C., et al (2008). Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metabolism and Disposition, 36(2), 205-216. [More Information]
  • Chua, W., Beale, P., Clarke, S., Leung, M. (2008). Retrospective review of mitomycin C use as third-line chemotherapy in metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 4(3), 132-136.
  • Zalcberg, J., Rosen, L., Abdi, E., Davis, I., Gutheil, J., Schnell, F., Cesano, A., Gayko, U., Chen, M., Clarke, S. (2008). Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer. Journal of Clinical Oncology, 26(8), 1386-1387. [More Information]
  • Sharma, R., Zucknick, M., London, R., Kacevska, M., Liddle, C., Clarke, S. (2008). Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clinical Colorectal Cancer, 7(5), 331-337. [More Information]
  • Sharma, R., Hoskins, J., Rivory, L., Zucknick, M., London, R., Liddle, C., Clarke, S. (2008). Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clinical Cancer Research, 14(3), 817-825. [More Information]
  • Yeo, W., Boyer, M., Chung, H., Ong, S., Lim, R., Zee, B., Ma, B., Lam, K., Mo, F., Ng, E., Clarke, S., Beale, P., et al (2007). Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemotherapy and Pharmacology, 59(3), 295-300. [More Information]
  • Clarke, S., Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S. (2007). Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. Clinical Colorectal Cancer, 6(8), 578-582. [More Information]
  • Chuah, B., Lim, R., Boyer, M., Ong, A., Wong, S., Kong, H., Millward, M., Clarke, S., Goh, B. (2007). Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncologica, 46(2), 234-238. [More Information]
  • Li, K., Rivory, L., Clarke, S. (2007). Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules. British Journal of Cancer, 97(8), 1071-1076. [More Information]
  • Harrison, J., Solomon, M., Young, J., Meagher, A., Hruby, G., Salkeld, G., Clarke, S. (2007). Surgical and oncology trials for rectal cancer: Who will participate? Surgery, 142(1), 94-101. [More Information]
  • McKay, M., Sherman, J., Laver, M., Baker, M., Clarke, S., Molloy, M. (2007). The development of multiple reaction monitoring assays for liver-derived plasma proteins. Proteomics - Clinical Applications, 1(12), 1570-1581. [More Information]
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Tattersall, M., Goldstein, D. (2007). When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer. Journal of Clinical Oncology, 25(18S), 6509.
  • Sharma, R., Rivory, L., Beale, P., Ong, S., Horvath, L., Clarke, S. (2006). A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. British Journal of Cancer, 94(7), 964-968. [More Information]
  • Tobin, P., Beale, P., Noney, L., Liddell, S., Rivory, L., Clarke, S. (2006). A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 57(3), 309-316. [More Information]
  • Mitchell, P., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Thomson, J., Clarke, S. (2006). Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clinical Colorectal Cancer, 6(2), 146-151. [More Information]
  • Nordman, I., Iyer, S., Joshua, A., Clarke, S. (2006). Advances in the adjuvant treatment of colorectal cancer. ANZ Journal of Surgery, 76(5), 373-380. [More Information]
  • Li, K., Rivory, L., Hoskins, J., Sharma, R., Clarke, S. (2006). Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. British Journal of Clinical Pharmacology, 63(1), 67-74. [More Information]
  • Read, J., Choy, S., Beale, P., Clarke, S. (2006). An evaluation of the prevalence of malnutrition in cancer patients attending the outpatient oncology clinic. Asia-Pacific Journal of Clinical Oncology, 2(2), 80-86.
  • Clarke, S., Sharma, R. (2006). Angiogenesis inhibitors in cancer - mechanisms of action. Australian Prescriber, 29(1), 9-12.
  • Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]
  • Read, J., Choy, S., Beale, P., Clarke, S. (2006). Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutrition and Cancer: an international journal, 55(1), 78-85. [More Information]
  • Read, J., Beale, P., Volker, D., Smith, N., Childs, A., Clarke, S. (2006). Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Supportive Care in Cancer, 15(3), 301-307. [More Information]
  • Rosen, L., Abdi, E., Davis, I., Gutheil, J., Schnell, F., Zalcberg, J., Cesano, A., Gayko, U., Chen, M., Clarke, S. (2006). Palifermin Reduces the Incidence of Oral Mucositis in Patients With Metastatic Colorectal Cancer Treated With Fluorouracil-Based Chemotherapy. Journal of Clinical Oncology, 24, 5194-5200. [More Information]
  • Aggarwal, G., Glare, P., Clarke, S., Chapuis, P. (2006). Palliative and shared care concepts in patients with advanced colorectal cancer. ANZ Journal of Surgery, 76(3), 175-180. [More Information]
  • Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
  • Michael, M., Goldstein, D., Clarke, S., Milner, A., Beale, P., Friedlander, M., Mitchell, P. (2006). Prognostic Factors Predictive of Response and Survival to a Modified FOLFOX Regimen: Importance of an Increased Neutrophil Count. Clinical Colorectal Cancer, 6(4), 297-304.
  • Michael, M., Thompson, M., Hicks, R., Mitchell, P., Ellis, A., Milner, A., Di Iulio, J., Scott, A., Gurtler, V., Clarke, S., Zalcberg, J., et al (2006). Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination. Journal of Clinical Oncology, 24(26), 4228-4235. [More Information]
  • Li, K., Rivory, L., Clarke, S. (2006). Solid-phase extraction (SPE) techniques for sample preparation in clinical and pharmaceutical analysis: A brief overview. Current Pharmaceutical Analysis, 2(2), 95-102.
  • Tobin, P., Clarke, S., Seale, J., Lee, S., Solomon, M., Aulds, S., Crawford, M., Gallagher, J., Eyers, T., Rivory, L. (2006). The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. British Journal of Clinical Pharmacology, 62(1), 122-129. [More Information]
  • Ackland, S., Clarke, S., Beale, P., Peters, G. (2006). Thymidylate synthase inhibitors. Update on Cancer Therapeutics, 1(4), 403-427.
  • Charles (nee Slaviero), K., Rivory, L., Brown, S., Liddle, C., Clarke, S., Robertson, G. (2006). Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clinical Cancer Research, 12(24), 7492-7497. [More Information]
  • Clarke, S., Boyer, M., Millward, M., Underhill, C., Moylan, E., Yip, D., White, S., Childs, A., Beale, P., Latz, J., et al (2005). A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer, 49(3), 401-412. [More Information]
  • Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Clarke, S. (2005). Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. British Journal of Cancer, 92(5), 832-837. [More Information]
  • Sharpe, L., Butow, P., Smith, C., McConnell, D., Clarke, S. (2005). Changes in quality of life in patients with advanced cancer - Evidence of response shift and response restriction. Journal of Psychosomatic Research, 58(6), 497-504. [More Information]
  • Vardy, J., Clarke, S. (2005). Ewing''s sarcoma of the rectum: Are four cycles of chemotherapy enough? Reply. Journal of Clinical Oncology, 23(24), 5850-5850.
  • Sharma, R., Boyer, M., Clarke, S., Millward, M. (2005). Gefitinib in advanced non-small cell lung cancer. Internal Medicine Journal, 35(2), 77. [More Information]
  • Joshua, A., Cotroneo, A., Clarke, S. (2005). Humor and oncology. Journal of Clinical Oncology, 23(3), 645-648.
  • Read, J., Beale, P., Horvath, L., Volker, D., Childs, A., Smith, N., Clarke, S. (2005). Impact of fish-oil supplement on nutritional parameters, inflammation and chemotherapy induced toxicity in colorectal cancer (CRC) patients receiving FOLFIRI - A pilot study. Journal of Clinical Oncology, 23(16S (supplement)), Abstract 8243 S789-S789.
  • Sharma, R., Tobin, P., Clarke, S. (2005). Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncology, 6(2), 93-102. [More Information]
  • Read, J., Crockett, N., Volker, D., MacLennan, P., Choy, S., Beale, P., Clarke, S. (2005). Nutritional assessment in cancer: comparing the Mini-Nutritional Assessment (MNA) with the scored Patient-Generated Subjective Global Assessment (PGSGA). Nutrition and Cancer: an international journal, 53(1), 51-56. [More Information]
  • Li, K., Rivory, L., Clarke, S. (2005). Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 820(1), 121-30. [More Information]
  • Joshua, A., Adams, D., McKenzie, P., Solomon, M., Clarke, S. (2005). Small blue cell tumors of the rectum. Case 2. Small-cell carcinoma of the rectum. Journal of Clinical Oncology, 23(4), 912-3. [More Information]
  • Sharma, R., McLeod, D., Clarke, S. (2005). Small blue cell tumors of the rectum. Case 3. Atypical carcinoid of the rectum. Journal of Clinical Oncology, 23(4), 914-5. [More Information]
  • Vardy, J., Joshua, A., Clarke, S., Yarrow, P., Lin, B. (2005). Small blue cell tumors of the rectum: CASE 1. Ewing's sarcoma of the rectum. Journal of Clinical Oncology, 23(4), 910-912. [More Information]
  • Joshua, A., Adams, D., McKenzie, P., Solomon, M., Clarke, S. (2005). Small Blue Cell Tumors of the Rectum: CASE 2. Small-Cell Carcinoma of the Rectum. Journal of Clinical Oncology, 23(4), 912-913.
  • Sharma, R., McLeod, D., Clarke, S. (2005). Small Blue Cell Tumors of the Rectum: CASE 3. Atypical Carcinoid of the Rectum. Journal of Clinical Oncology, 23(4), 914-915.
  • Joshua, A., Boyer, M., Subramanian, R., Clarke, S. (2005). Smoking reduction does work: resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years. Respirology, 10(2), 233-238. [More Information]
  • Sharpe, L., Butow, P., Smith, C., McConnell, D., Clarke, S. (2005). The relationship between available support, unmet needs and caregiver burden in patients with advanced cancer and their carers. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 14(2), 102-114. [More Information]
  • Joshua, A., Nordman, I., Venkataswaran, R., Clarke, S., Stockler, M., Boyer, M. (2005). Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Internal Medicine Journal, 35(8), 468-472. [More Information]
  • Baker, S., Van Schaik, R., Rivory, L., Ten Tije, A., Dinh, K., Graveland, W., Schenk, P., Charles, J., Clarke, S., Carducci, M., Sparreboom, A., et al (2004). Factors Affecting Cytochrome P-450 3A Activity In Cancer Patients. Clinical Cancer Research, 10(12), 8341-8350.
  • Tobin, P., Rivory, L., Clarke, S. (2004). Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11). Pharmacology and Therapeutics, 76(5), 505-506.
  • Vardy, J., Engelhardt, K., Cox, K., Jacquet, J., McDade, A., Boyer, M., Beale, P., Clarke, S., Stockler, M., Loneragan, R., Waugh, R., Clarke, S. (2004). Long-Term Outcome Of Radiological-Guided Insertion Of Implanted Central Venous Access Port Devices (Cvapd) For The Delivery Of Chemotherapy In Cancer Patients: Institutional Experience And Review Of The Literature. British Journal of Cancer, 91(6), 1045-1049.
  • Blair, E., Rivory, L., Clarke, S., McLachlan, A. (2004). Population Pharmacokinetics Of Raltitrexed In Patients With Advanced Solid Tumours. British Journal of Clinical Pharmacology, 57(4), 416-426.
  • Charles (nee Slaviero), K., Clarke, S., McLachlan, A., Blair, E., Rivory, L. (2004). Population Pharmacokinetics Of Weekly Docetaxel In Patients With Advanced Cancer. British Journal of Clinical Pharmacology, 57(1), 44-53.
  • Zhang, M., Boyer, M., Rivory, L., Hong, A., Clarke, S., Stevens, G., Fife, K. (2004). Radiosensitization Of Vinorelbine And Gemcitabine In Nci-H460 Non-Small-Cell Lung Cancer Cells. International Journal of Radiation: Oncology - Biology - Physics, 58(2), 353-360. [More Information]
  • Featherstone, C., Clarke, S., Jackson, M., Shannon, K., McNeil, E., Tin, M., Clifford, A., O'Brien, C. (2004). Treatment Of Advanced Cancer Of The Larynx And Hypopharynx With Chemoradiation. ANZ Journal of Surgery, 74(7), 554-558.
  • Smit, E., Mattson, K., von Pawel, J., Manegold, C., Clarke, S., Postmus, P. (2003). ALIMTA® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Annals of Oncology, 14(3), 455-460.
  • Clarke, S. (2003). An 85-year old woman with metastatic liver disease: clinical case review. Medicine Today, 4(1), 72-73.
  • Charles (nee Slaviero), K., Read, J., Clarke, S., Rivory, L. (2003). Baseline Nutritional Assessment in Advanced Cancer Patients Receiving Palliative Chemotherapy. Nutrition and Cancer: an international journal, 46(2), 148-157.
  • Tattersall, M., Clarke, S. (2003). Developments in drug delivery: implications for cancer care. Current Opinion in Oncology, 15(4), 293-299.
  • Charles (nee Slaviero), K., Clarke, S., Rivory, L. (2003). Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncology, 4(4), 224-232.
  • Saw, R., Morgan, M., Koorey, D., Painter, D., Findlay, M., Stevens, G., Clarke, S., Chapuis, P., Solomon, M. (2003). P53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Diseases of the Colon and Rectum, 46(2), 192-202. [More Information]
  • Li, K., Clarke, S., Rivory, L. (2003). Quantitation of plasma thymidine by high-performance liquid chromatography - atmospheric pressure chemical ionization mass spectromentry and its application to pharmocodynamic studies in cancer patients. Analytica Chimica Acta, 486(1), 51-61.
  • Tobin, P., Dodds, H., Clarke, S., Schnitzler, M., Rivory, L. (2003). The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours. Oncology reports, 10(6), 1977-1979.
  • Aristides, M., Chen, J., Schulz, M., Williamson, E., Clarke, S., Grant, K. (2002). Conjoint analysis of a new chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced colorectal cancer. PharmacoEconomics, 20(11), 775-784.
  • Cunningham, D., Zalcberg, J., Maroun, J., James, R., Clarke, S., Maughan, T., Vincent, M., Schulz, J., Gonzalez Baron, M., Facchini, T. (2002). Efficacy, tolerability and management of raltitrexed (Tomudex TM) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials. European Journal of Cancer, 38(4), 478-486.
  • Rivory, L., Charles (nee Slaviero), K., Clarke, S. (2002). Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. British Journal of Cancer, 87(3), 277-280.
  • Vardy, J., Wong, E., Izard, M., Clifford, A., Clarke, S. (2002). Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review. Anti-Cancer Drugs, 13(3), 327-330.
  • Clarke, S. (2002). New treatments for advanced and metastatic colorectal cancer - clinical applications. Australian Prescriber, 25(5), 111-113.
  • Rischin, D., Ackland, S., Smith, J., Garg, M., Clarke, S., Millward, M., Toner, G., Zalcberg, J. (2002). Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies. Annals of Oncology, 13(11), 1810-1818.
  • Clarke, S., Abratt, R., Goedhals, L., Boyer, M., Millward, M., Ackland, S. (2002). Phase II trial of pemetrexed disodium (ALIMTA[R], LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Annals of Oncology, 13(5), 737-741.
  • Rivory, L., Clarke, S., Boyer, M., Bishop, J. (2001). Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 765, 135-140.
  • Rivory, L., Charles (nee Slaviero), K., Hoskins, J., Clarke, S. (2001). The erythromycin breath test for the prediction of drug clearance. Clinical Pharmacokinetics, 40, 151-158.
  • Clarke, S., Bishop, J., Dodds, H., Rivory, L., Ong,, S. (2001). Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anti-Cancer Drugs, 12, 619-625.
  • Clarke, S., Beale, P., Rivory, L. (2000). Clinical and preclinical pharmacokinetics of raltitrexed. Clinical Pharmacokinetics, 39, 429-443.

Conferences

  • Clarke, S. (2013). A Medical Oncology Approach to Colorectal Cancer. Cancer Nurses Society of Australia Educational Event 2011.
  • Clarke, S. (2013). An Australian Translational Study to Evaluate the Prognostic Role of lnflammatorv Markers in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab (Avastin TM ) [ASCENT]. 2012 COSA 39th Annual Scientific Meeting.
  • Clarke, S. (2012). Comparison of nutritional assessment with a new definition of cachexia in determining outcomes of advanced cancer patients. European Society of Medical Oncology 2012 Congress.
  • Clarke, S. (2012). Lower Gastrointestinal Cancers Update. 2012 Roche Products Adelaide Post-ASCO Education Meeting.
  • Clarke, S. (2012). Plasma biomarkers of outcome in CRC. Merck Serono Australia Tailored Therapies Meeting- The New Era- Focus on Colorectal Cancer.
  • Clarke, S. (2012). Predictive and prognostics factors associated with Mesothelioma and Lung Cancer. Lilly Oncology Australian Scientific Exchange Meeting 2012.
  • Clarke, S. (2012). Prognostic Factors in Colorectal Cancer. Roche Haematology & Oncology Targeted Therapies (HOTT) Symposium 2012.
  • Clarke, S. (2012). Translational research at the Kolling Institute of Medical Research. 5th Annual Hunter Cancer Research Symposium.
  • Clarke, S. (2012). What are a treating team's obligations to ensure access to treatment and compensation for mesothelioma sufferers? 4th Australian Lung Cancer Conference.
  • Clarke, S. (2011). Bone Metastases. Nuclear Medicine Society NSW Educational Meeting.
  • Clarke, S. (2011). Cancer in Northern Sydney. Kolling Institute of Medical Research Public Forum "Our Fight Against Cancer".
  • Clarke, S. (2011). Plenary address: Cancer Research at the Universitv of Sydney. Cancer Research Network Postgraduate Symposium 2011.
  • Clarke, S. (2011). Predicting outcomes in Lung Cancer. The Second Oncology Forum of Chinese Physicians from China and the US (OFCCU).
  • Clarke, S. (2011). Predicting outcomes of cancer treatment. 2011 ARCS Scientific Congress.
  • Clarke, S. (2011). Update on Neuroendocrine. Endocrine and Oncology Nurses of Australia Symposium.
  • Clarke, S. (2011). Use of the neutrophil lymphocyte ratio to predict outcomes from chemotherapy. Medical Oncology Group of Australia Limited Annual Scientific Meeting 2011, Adelaide, South Australia: Medical Oncology Group of Australia.
  • Clarke, S. (2010). Evaluating Chemotherapy Toxicity/Antimetabolite Chemotherapy. Medical Oncology Group of Australia Basic Sciences of Oncology Program 2010.
  • Clarke, S. (2010). Interacting with Pharma. 2010 Joint MOGA and Private Cancer Physicians of Australia.
  • Clarke, S. (2010). lndividualisation of Chemotherapy in Colorectal Cancer. Colorectal Cancer - A Multidisciplinary Approach Meeting.
  • Clarke, S. (2010). Options in Academia. Pfizer Advanced Trainee Education Meeting.
  • Clarke, S. (2010). Predictors of outcomes in colorectal cancer. Ludwig Institute Colon Cancer Symposium.
  • Clarke, S. (2010). Updates in Medical Oncology. 2010 ARCS Australia Annual Scientific Congress.
  • Clarke, S. (2009). Advanced colorectal cancer - where are we going? AstraZeneca Challenges in Gastroenterology Symposium.
  • Clarke, S. (2009). Chemotherapy and timing of surgery. Australia & New Zealand Medical & Surgical Gastrointestinal Week 2009.
  • Clarke, S. (2009). Interactions with cancer therapies. Clinical Oncological Society of Australia 36th Annual Scientific Meeting: Awareness, Access, Action.
  • Clarke, S. (2009). Managing complex/multiple focus disease areas & networks: the cancer experience. National Institute of Complementary Medicine 2009 National Symposium: Supporting health priorities & industry growth.
  • Clarke, S. (2009). Plasma proteomic predictors of response and toxicitv in colorectal cancer patients receiving chemotherapy. 2nd Sino-Australian Symposium, N/A: N/A.
  • Clarke, S. (2009). Systemic therapy for Malignant Mesothelioma: An Overview. ANZAC Research Institute’s 8th Annual Symposium.
  • Clarke, S. (2008). DaVINCI Trial Update and Issues in 2nd line chemotherapy. 10th Annual Scientific Meeting of Australasian Gastro-Intestinal Trials Group.
  • Clarke, S. (2008). Differences in Chemotherapy. 1st Sino-Australian Symposium.
  • Clarke, S. (2008). Inflammation and cancer drug metabolism. Sydney Cancer Conference 2008 (SCC2008), Sydney: University of Sydney.
  • Clarke, S. (2008). Inflammation, drug metabolism and chemotherapy toxicity. Hunter Medical Research Institute Conference on Translational Cancer Research.
  • Clarke, S. (2008). Inflammatory Response: An unrecognized source of variability in PK/PD of cancer chemotherapy. ASCPT 2008 Annual Meeting.
  • Clarke, S. (2008). Infusion vs bolus chemotherapy for colon cancer/Stage II Colon Cancer: Is adjuvant chemotherapy necessary? National Cancer Control Network 1st Asian Scientific Meeting.
  • Clarke, S. (2008). New developments in the practice of lung cancer. The Oncology Forum of Chinese Physicians from China and the US (OFCCU).
  • Clarke, S. (2008). Predicting toxicity from chemotherapy. The Australian Health & Medical Research Congress 2008.
  • Sobrero, A., Ackland, S., Perez-Carrion, R., Chiara, S., Clarke, S., Giron, C., Langer, B., Zurlo, A., Young, S. (2006). Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer. 2006 American Society of Clinical Oncology (ASCO) Annual Meeting, United States: American Society of Clinical Oncology.
  • Haller, D., Cassidy, J., Clarke, S., Cunningham, D., Van Cutsem, E., Hoff, P., Rothenberg, M., Saltz, L., Schmoll, H., Twelves, C. (2006). Tolerability of fluoropyrimidines appears to differ by region. 2006 ASCO Annual Meeting, United Kingdom: Oxford University Press.
  • Tobin, P., Seale, P., Lee, S., Solomon, M., Fields, S., Rivory, L., Clarke, S. (2005). The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. 2005 American Society of Clinical Oncology (ASCO) Annual Meeting, United States: American Society of Clinical Oncology.
  • Clarke, S., Boyer, M., Stockler, M., Venkatawaran, R., Nordman, I., Joshua, A. (2005). Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC). 2005 ASCO Annual Meeting, NY, USA: American Society of Clinical Oncology.

2014

  • Wang, F., Gill, A., Neale, M., Puttaswamy, V., Gananadha, S., Pavlakis, N., Clarke, S., Hugh, T., Samra, J. (2014). Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 21(6), 1937-1947. [More Information]
  • Chik, J., Zhou, J., Moh, E., Christopherson, R., Clarke, S., Molloy, M., Packer, N. (2014). Comprehensive glycomics comparison between colon cancer cell cultures and tumours: Implications for biomarker studies. International Journal of Proteomics, 108(C), 146-162. [More Information]
  • Tsoli, M., Schweiger, M., Vanniasinghe, A., Painter, A., Zechner, R., Clarke, S., Robertson, G. (2014). Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation. PLoS One, 9(3), e92966- 1-e92966- 12. [More Information]
  • Hayes, S., Hudson, A., Clarke, S., Molloy, M., Howell, V. (2014). From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell & Developmental Biology, 27, 118-127. [More Information]
  • Kohonen-Corish, M., Tseung, J., Chan, C., Currey, N., Dent, O., Clarke, S., Chapuis, P. (2014). KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. International Journal of Cancer, 134, 2820-2828. [More Information]

2013

  • Clarke, S. (2013). A Medical Oncology Approach to Colorectal Cancer. Cancer Nurses Society of Australia Educational Event 2011.
  • Hibbert, E., Lambert, T., Carter, J., Learoyd, D., Twigg, S., Clarke, S. (2013). A randomized controlled pilot trial comparing the impact of access to clinical endocrinology video demonstrations with access to usual revision resources on medical student performance of clinical endocrinology skills. BMC Medical Education, 13(1), 1-10. [More Information]
  • Clarke, S., Burge, M., Cordwell, C., Gibbs, P., Reece, W., Tebbutt, N. (2013). An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (AvastinTM) [ASCENT]. BMC Cancer, 13, 1-7. [More Information]
  • Clarke, S. (2013). An Australian Translational Study to Evaluate the Prognostic Role of lnflammatorv Markers in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab (Avastin TM ) [ASCENT]. 2012 COSA 39th Annual Scientific Meeting.
  • Toon, C., Walsh, M., Chou, A., Capper, D., Clarkson, A., Sioson, L., Clarke, S., Mead, S., Walters, R., Clendenning, M., Gill, A., et al (2013). BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. American Journal of Surgical Pathology, 37(10), 1592-1602. [More Information]
  • Elens, L., Nieuweboer, A., Clarke, S., Charles (nee Slaviero), K., De Graan, A., Haufroid, V., Mathijssen, R., Van Schaik, R. (2013). CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics, 14(2), 137-149. [More Information]
  • Kao, S., Lee, K., Klebe, S., Henderson, D., McCaughan, B., Vardy, J., Clarke, S., van Zandwijk, N. (2013). Excision Repair Cross Complementation Group 1 and Thymidylate Synthase Expression in Patients With Mesothelioma. Clinical Lung Cancer, 14(2), 164-171. [More Information]
  • Kacevska, M., Mahns, A., Sharma, R., Clarke, S., Robertson, G., Liddle, C. (2013). Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling. Pharmaceutical Research, 30(9), 2270-2278. [More Information]
  • Linton, A., Pond, G., Clarke, S., Vardy, J., Galsky, M., Sonpavde, G. (2013). Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy. Clinical Genitourinary Cancer, 11(4), 423-430. [More Information]
  • Kao, S., Vardy, J., Harvie, R., Chatfield, M., van Zandwijk, N., Clarke, S., Pavlakis, N. (2013). Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Supportive Care in Cancer, 21(3), 697-705. [More Information]
  • Linton, A., Kao, S., Vardy, J., Clarke, S., van Zandwijk, N., Klebe, S. (2013). Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review. Asia-Pacific Journal of Clinical Oncology, 9(3), 273-279. [More Information]
  • Elens, L., Nieuweboer, A., Clarke, S., Charles (nee Slaviero), K., De Graan, A., Haufroid, V., van Gelder, T., Mathijssen, R., Van Schaik, R. (2013). Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and Genomics, 23(3), 148-155. [More Information]
  • Vardy, J., Dhillon, H., Clarke, S., Olesen, I., Leslie, F., Warby, A., Beith, J., Sullivan, A., Hamilton, A., Beale, P., Rittau, A., McLachlan, A. (2013). Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. SpringerPlus, 2(1), 1-5. [More Information]
  • Clarke, S., Karapetis, C., Gibbs, P., Pavlakis, N., Desai, J., Michael, M., Tebbutt, N., Price, T., Tabernero, J. (2013). Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. Critical Reviews in Oncology / Hematology (online), 85(2), 121-135. [More Information]
  • Kao, S., Clarke, S., Vardy, J., Corte, P., Clarke, C., van Zandwijk, N. (2013). Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. Internal Medicine Journal, 43(4), 402-410. [More Information]
  • Jankova, L., Dent, O., Chan, C., Chapuis, P., Clarke, S. (2013). Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer-specific survival after curative resection of node-positive colorectal cancer. BMC Cancer, 13, 1-13. [More Information]
  • Stein, R., Sharpe, L., Bell, M., Boyle, F., Dunn, S., Clarke, S. (2013). Randomized Controlled Trial of a Structured Intervention to Facilitate End-of-Life Decision Making in Patients With Advanced Cancer. Journal of Clinical Oncology, 31(27), 3403-3410. [More Information]
  • Hasovits, C., Pavlakis, N., Howell, V., Gill, A., Clarke, S. (2013). Resistance to EGFR targeted antibodies - expansion of clones present from the start of treatment. The more things change, the more they stay the same (Plus ca change, plus ca ne change pas!). Translational Gastrointestinal Cancer, 28(1), 44-46. [More Information]
  • Guthrie, G., Charles (nee Slaviero), K., Roxburgh, C., Horgan, P., McMillan, D., Clarke, S. (2013). The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Critical Reviews in Oncology / Hematology (online), 88(1), 218-230. [More Information]
  • Findlay, M., Bauer, J., Clarke, S., Isenring, E. (2013). Understanding nutritional issues in the older person with cancer. Cancer Forum, 37(3), 234-237.
  • Kao, S., van Zandwijk, N., Corte, P., Clarke, C., Clarke, S., Vardy, J. (2013). Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. Supportive Care in Cancer, 21(7), 1879-1884. [More Information]
  • Kao, S., Vardy, J., Chatfield, M., Corte, P., Pavlakis, N., Clarke, C., van Zandwijk, N., Clarke, S. (2013). Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board. Clinical Lung Cancer, 14(1), 70-77. [More Information]
  • de Marinis, F., Clarke, S. (2013). Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer. Lung Cancer, 82(3), 511-511. [More Information]

2012

  • Oh, B., Butow, P., Mullan, B., Hale, A., Lee, M., Guo, X., Clarke, S. (2012). A Critical Review of the Effects of Medical Qigong on Quality of Life, Immune Function, and Survival in Cancer Patients. Integrative Cancer Therapies, 11(2), 101-110. [More Information]
  • Proctor, M., McMillan, D., Morrison, D., Fletcher, C., Horgan, P., Clarke, S. (2012). A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. British Journal of Cancer, 107(4), 695-699. [More Information]
  • Michael, M., Pavlakis, N., Clingan, P., de Boer, R., Johnston, M., Clarke, S. (2012). A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. Oncology reports, 28(3), 763-767. [More Information]
  • Tsoli, M., Moore, M., Burg, D., Painter, A., Taylor, R., Lockie, S., Turner, N., Warren, A., Cooney, G., Oldfield, B., Clarke, S., et al (2012). Activation of Thermogenesis in Brown Adipose Tissue and Dysregulated Lipid Metabolism Associated with Cancer Cachexia in Mice. Cancer Research, 72(17), 4372-4382. [More Information]
  • De Gramont, A., Van Cutsem, E., Schmoll, H., Tabernero, J., Clarke, S., Moore, M., Cunningham, D., Cartwright, T., Hecht, J., Rivera, F., et al (2012). Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncology, 13(12), 1225-1233. [More Information]
  • Bullen, T., Sharpe, L., Lawsin, C., Patel (nee Chauhan), D., Clarke, S., Bokey, E. (2012). Body image as a predictor of psychopathology in surgical patients with colorectal disease. Journal of Psychosomatic Research, 73(6), 459-463. [More Information]
  • Davis, E., Oh, B., Butow, P., Mullan, B., Clarke, S. (2012). Cancer Patient Disclosure and Patient-Doctor Communication of Complementary and Alternative Medicine Use: A Systematic Review. The Oncologist, 17(11), 1475-1481. [More Information]
  • Clarke, S. (2012). Comparison of nutritional assessment with a new definition of cachexia in determining outcomes of advanced cancer patients. European Society of Medical Oncology 2012 Congress.
  • Shum, A., Mahendradatta, T., Taylor, R., Painter, A., Moore, M., Tsoli, M., Tan, T., Clarke, S., Robertson, G., Polly, P. (2012). Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging, 4(2), 133-143. [More Information]
  • Michael, M., Cullinane, C., Hatzimihalis, A., O'Kane, C., Milner, A., Booth, R., Schlicht, S., Clarke, S., Francis, P. (2012). Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. Cancer Chemotherapy and Pharmacology, 69(1), 125-135. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Lee, M., Rosenthal, D., Larkey, L., Vardy, J. (2012). Effect of Medical Qigong on Cognitive function, Quality of Life and a Biomarker of Inflammation in Cancer Patients: A Randomized Controlled Trial. Supportive Care in Cancer, 20(6), 1235-1242. [More Information]
  • Jankova, L., Robertson, G., Chan, C., Tan, K., Kohonen-Corish, M., Fung, C., Clarke, C., Lin, B., Molloy, M., Chapuis, P., Bokey, E., Dent, O., Clarke, S. (2012). Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study. BMC Cancer, 12, 1-9. [More Information]
  • Clarke, S., McLachlan, A. (2012). Interaction Between Complementary and Alternative Medicines and Conventional Medicines. In Olver, I and Robotin, M (Eds.), Perspectives on Complementary and Alternative Medicines, (pp. 227-259). London: Imperial College Press.
  • Clarke, S. (2012). Lower Gastrointestinal Cancers Update. 2012 Roche Products Adelaide Post-ASCO Education Meeting.
  • Kho, P., Jankova, L., Fung, C., Chan, C., Clarke, C., Lin, B., Robertson, G., Molloy, M., Chapuis, P., Bokey, E., Dent, O., Clarke, S. (2012). Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front. International Journal of Colorectal Disease: clinical and molecular gastroenterology and surgery, 27(11), 1409-1417. [More Information]
  • Van Der Wall, H., Elison, B., Frater, C., Bruce, W., Clarke, S. (2012). Pathophysiology of Bone Metastases. In Ignac Fogelman, Gopinath Gnanasegaran, Hans Van der Wall. (Eds.), Radionuclide and Hybrid Bone Imaging, (pp. 59-84). Heidelberg: Springer.
  • Hasovits, C., Clarke, S. (2012). Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics. Clinical Pharmacokinetics, 51(4), 203-224. [More Information]
  • Clarke, S. (2012). Plasma biomarkers of outcome in CRC. Merck Serono Australia Tailored Therapies Meeting- The New Era- Focus on Colorectal Cancer.
  • Clarke, S. (2012). Predictive and prognostics factors associated with Mesothelioma and Lung Cancer. Lilly Oncology Australian Scientific Exchange Meeting 2012.
  • Clarke, S. (2012). Prognostic Factors in Colorectal Cancer. Roche Haematology & Oncology Targeted Therapies (HOTT) Symposium 2012.
  • Randall, S., McKay, M., Pascovici, D., Mahon, K., Horvath, L., Clarke, S., Molloy, M. (2012). Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. Proteomics - Clinical Applications, 6(11-12), 626-634. [More Information]
  • Chua, W., Horvath, L., Beale, P., Clarke, S. (2012). Reporting clinical trial information: colorectal cancer trials at Sydney Cancer Centre. Internal Medicine Journal, 42(4), 416-421. [More Information]
  • Chellappa, K., Jankova, L., Schnabl, J., Pan, S., Brelivet, Y., Fung, C., Chan, C., Dent, O., Clarke, S., Robertson, G., et al (2012). Src tyrosine kinase phosphorylation of nuclear receptor HNF4a correlates with isoform-specific loss of HNF4a in human colon cancer. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 109(7), 2302-2307. [More Information]
  • Chua, W., Clarke, S., Charles (nee Slaviero), K. (2012). Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Supportive Care in Cancer, 20(8), 1869-1874. [More Information]
  • Clarey, J., Kao, S., Clarke, S., Vardy, J. (2012). The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials. Annals of Oncology, 23(5), 1229-1233. [More Information]
  • Dhillon, H., Van Der Ploeg, H., Bell, M., Boyer, M., Clarke, S., Vardy, J. (2012). The impact of physical activity on fatigue and quality of life in lung cancer patients: A randomised controlled trial protocol. BMC Cancer, 12, 1-9. [More Information]
  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012). The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer, 75(2), 248-254. [More Information]
  • Linton, A., Vardy, J., Clarke, S., van Zandwijk, N. (2012). The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma. Critical Reviews in Oncology / Hematology (online), 84(2), 200-212. [More Information]
  • Clarke, S. (2012). Translational research at the Kolling Institute of Medical Research. 5th Annual Hunter Cancer Research Symposium.
  • Kho, P., Chapuis, P., Beale, P., Bokey, E., Dent, O., Clarke, S. (2012). Use of adjuvant chemotherapy in stage C (III) rectal cancer: Comparison of data from matched patients in a teaching hospital's clinico-pathological database. Asia-Pacific Journal of Clinical Oncology, 8(4), 346-355. [More Information]
  • Clarke, S. (2012). What are a treating team's obligations to ensure access to treatment and compensation for mesothelioma sufferers? 4th Australian Lung Cancer Conference.

2011

  • Kao, S., Yan, T., Lee, K., Burn, J., Henderson, D., Klebe, S., Kennedy, C., Vardy, J., Clarke, S., Van Zandwijk, N., et al (2011). Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. Journal of Thoracic Oncology, 6(3), 602-605. [More Information]
  • Phan, V., Tan, C., Rittau, A., Xu, H., McLachlan, A., Clarke, S. (2011). An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 7(11), 1395-1410. [More Information]
  • Clarke, S. (2011). Bone Metastases. Nuclear Medicine Society NSW Educational Meeting.
  • Clarke, S. (2011). Cancer in Northern Sydney. Kolling Institute of Medical Research Public Forum "Our Fight Against Cancer".
  • Fung, D., Lo, A., Jankova, L., Clarke, S., Molloy, M., Robertson, G., Wilkins, M. (2011). Classification of Cancer Patients Using Pathway Analysis and Network Clustering. In Gerard Cagney, Andrew Emili (Eds.), Network Biology: Methods and Applications, (pp. 311-336). New York: Humana Press.
  • He, X., Clarke, S., McLachlan, A. (2011). Clinical pharmacology of chemotherapy agents in older people with cancer. Current Gerontology and Geriatrics Research, 2011, 628670-1-628670-6. [More Information]
  • Chua, W., Kho, P., Moore, M., Charles (nee Slaviero), K., Clarke, S. (2011). Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Critical Reviews in Oncology / Hematology, 79(3), 224-250. [More Information]
  • Tan, K., Jankova, L., Chan, C., Fung, C., Clarke, C., Lin, B., Robertson, G., Molloy, M., Chapuis, P., Bokey, E., Clarke, S., et al (2011). Clinicopathological correlates and prognostic significance of glutathione S-transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer. Histopathology, 59(6), 1057-1070. [More Information]
  • Zhou, J., Belov, L., Solomon, M., Chan, C., Clarke, S., Christopherson, R. (2011). Colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing. Journal of Visualized Experiments, (55), 1-6. [More Information]
  • Kacevska, M., Downes, M., Sharma, R., Evans, R., Clarke, S., Liddle, C., Robertson, G. (2011). Extrahepatic Cancer Suppresses Nuclear Receptor–Regulated Drug Metabolism. Clinical Cancer Research, 17(10), 3170-3180. [More Information]
  • Clarke, S., McLachlan, A. (2011). Interaction between complementary and alternative medicine with conventional anti-cancer medicine. Cancer Forum, 35(1), 18-23.
  • Lee, A., Chick, J., Kolarich, D., Haynes, P., Robertson, G., Tsoli, M., Jankova, L., Clarke, S., Packer, N., Baker, M. (2011). Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumour. Molecular and Cellular Proteomics, 10(9), 1-18. [More Information]
  • Kao, S., Klebe, S., Henderson, D., Reid, G., Chatfield, M., Armstrong, N., Yan, T., Vardy, J., Clarke, S., van Zandwijk, N., McCaughan, B. (2011). Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy. Journal of Thoracic Oncology, 6(11), 1923-1929. [More Information]
  • Chua, W., Charles (nee Slaviero), K., Baracos, V., Clarke, S. (2011). Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. British Journal of Cancer, 104(8), 1288-1295. [More Information]
  • Backshall, A., Sharma, R., Clarke, S., Keun, H. (2011). Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clinical Cancer Research, 17(9), 3019-3028. [More Information]
  • Clarke, S. (2011). Plenary address: Cancer Research at the Universitv of Sydney. Cancer Research Network Postgraduate Symposium 2011.
  • Clarke, S. (2011). Predicting outcomes in Lung Cancer. The Second Oncology Forum of Chinese Physicians from China and the US (OFCCU).
  • Clarke, S. (2011). Predicting outcomes of cancer treatment. 2011 ARCS Scientific Congress.
  • Jankova, L., Chan, C., Fung, C., Song, X., Kwun, S., Cowley, M., Kaplan, W., Dent, O., Bokey, E., Chapuis, P., Robertson, G., Clarke, S., et al (2011). Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Molecular BioSystems, 7(11), 2997-3005. [More Information]
  • Mitchell, P., Broad, A., Rosenthal, M., Galettis, P., Abraham, R., Burns, I., Clarke, S., Milner, A., Diiulio, J., Links, M. (2011). Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 7(4), 376-384. [More Information]
  • Oh, B., Hu, G., Kao, S., Gebski, V., Walls, R., Truong, L., Beale, P., Clarke, S. (2011). Safety and tolerability of Chinese Herbal Medicine with cancer patients receiving chemotherapy. WebmedCentral, 2(Article ID: WMC001671), 1-11.
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Clarke, S. (2011). Successes, challenges and future directions. In Dimitrios H Roukos (Eds.), Advances in Personalized Cancer Management, (pp. 84-95). London: Future Medicine Ltd.
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Goldstein, D., Horvath, L., Tattersall, M., et al (2011). Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of Clinical Oncology, 29(15), 2077-2084. [More Information]
  • Sharpe, L., Patel (nee Chauhan), D., Clarke, S. (2011). The relationship between body image disturbance and distress in colorectal cancer patients with and without stomas. Journal of Psychosomatic Research, 70(5), 395-402. [More Information]
  • Clarke, S. (2011). Update on Neuroendocrine. Endocrine and Oncology Nurses of Australia Symposium.
  • Clarke, S., Chua, W., Moore, M., Kao, S., Phan, V., Tan, C., Charles (nee Slaviero), K., McMillan, D. (2011). Use of inflammatory markers to guide cancer treatment. Clinical Pharmacology and Therapeutics, 90(3), 475-478. [More Information]
  • Clarke, S. (2011). Use of the neutrophil lymphocyte ratio to predict outcomes from chemotherapy. Medical Oncology Group of Australia Limited Annual Scientific Meeting 2011, Adelaide, South Australia: Medical Oncology Group of Australia.
  • Patel (nee Chauhan), D., Sharpe, L., Thewes, B., Bell, M., Clarke, S. (2011). Using the distress thermometer and hospital anxiety and depression scale to screen for psychosocial morbidity in patients diagnosed with colorectal cancer. Journal of Affective Disorders, 131(1-3), 412-416. [More Information]
  • Kao, S., Griggs, K., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Burn, J., McCaughan, B., Henderson, D., et al (2011). Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology, 43(4), 313-317. [More Information]
  • Kao, S., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Reid, G., Burn, J., McCaughan, B., Henderson, D., et al (2011). Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology, 43(2), 128-132. [More Information]
  • Cassidy, J., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Rittweger, K., Gilberg, F., Saltz, L. (2011). XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. British Journal of Cancer, 105(1 Spring 2010), 58-64. [More Information]

2010

  • Blinman, P., Duric, V., Nowak, A., Beale, P., Clarke, S., Briscoe, K., Boyce, A., Goldstein, D., Hudson, M., Stockler, M. (2010). Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile? European Journal of Cancer, 46(10), 1800-1807. [More Information]
  • Clarke, S., McLachlan, A., Brown, D., Carbonara, S., Kissane, R. (2010). Beyond Conventional Cancer Treatments: The Use of Complementary Therapies During Cancer Treatment: Implications for Clinicians. In Monica Robotin, Ian Olver and Afaf Girgis (Eds.), When Cancer Crosses Disciplines: A Physician's Handbook, (pp. 285-315). London: Imperial College Press.
  • Chua, W., Clarke, S. (2010). Clinical Trial Information As a Measure of Quality Cancer Care. Journal of Oncology Practice, 6(3), 170-171. [More Information]
  • Fung, C., Chan, C., Jankova, L., Dent, O., Robertson, G., Molloy, M., Bokey, E., Chapuis, P., Lin, B., Clarke, S. (2010). Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer. Histopathology, 56(3), 319-330. [More Information]
  • Clarke, S. (2010). Evaluating Chemotherapy Toxicity/Antimetabolite Chemotherapy. Medical Oncology Group of Australia Basic Sciences of Oncology Program 2010.
  • Chan, C., Jankova, L., Fung, C., Clarke, C., Robertson, G., Chapuis, P., Bokey, E., Lin, B., Dent, O., Clarke, S. (2010). Fascin Expression Predicts Survival After Potentially Curative Resection of Node-positive Colon Cancer. American Journal of Surgical Pathology, 34(5), 656-666. [More Information]
  • Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research, 16(23), 5805-5813. [More Information]
  • Lam, F., Jankova, L., Dent, O., Molloy, M., Kwun, S., Clarke, C., Chapuis, P., Robertson, G., Beale, P., Clarke, S., Bokey, E., Chan, C. (2010). Identification of distinctive protein expression patterns in colorectal adenoma. Proteomics - Clinical Applications, 4(1), 60-70. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Kothe, E., Lam, L., Rosenthal, D. (2010). Impact of Medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. Annals of Oncology, 21(3), 608-614. [More Information]
  • Moore, M., Chua, W., Charles (nee Slaviero), K., Clarke, S. (2010). Inflammation and Cancer: Causes and Consequences. Clinical Pharmacology and Therapeutics, 87(4), 504-508. [More Information]
  • Clarke, S. (2010). Interacting with Pharma. 2010 Joint MOGA and Private Cancer Physicians of Australia.
  • Kho, P., Chua, W., Moore, M., Clarke, S. (2010). Is it Prime Time for Personalized Medicine in Cancer Treatment? Personalized Medicine, 7(4), 387-397.
  • Clarke, S. (2010). lndividualisation of Chemotherapy in Colorectal Cancer. Colorectal Cancer - A Multidisciplinary Approach Meeting.
  • Kao, S., Reid, G., Lee, K., Vardy, J., Clarke, S., van Zandwijk, N. (2010). Malignant Mesothelioma. International Medical Journal. [More Information]
  • Clarke, S. (2010). Options in Academia. Pfizer Advanced Trainee Education Meeting.
  • Kao, S., Butow, P., Bray, V., Clarke, S., Vardy, J. (2010). Patient and oncologist estimates of survival in advanced cancer patients. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 10(2), 213-218.
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010). Patient-Doctor Communication: Use of Complementary and Alternative Medicine by Adult Patients with Cancer. Journal of the Society for Integrative Oncology, 8(2), 56-64. [More Information]
  • Kao, S., Phan, V., Clarke, S. (2010). Predictive Markers for Haematological Toxicity of Pemetrexed. Current Drug Targets, 11(1), 48-57. [More Information]
  • Clarke, S. (2010). Predictors of outcomes in colorectal cancer. Ludwig Institute Colon Cancer Symposium.
  • Zhou, J., Belov, L., Huang, P., Shin, J., Solomon, M., Chapuis, P., Bokey, E., Chan, C., Clarke, C., Clarke, S., Christopherson, R. (2010). Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. Journal of Immunological Methods, 355(40210 (1-2)), 40-51. [More Information]
  • Matic, M., Carradin, A., Tsoli, M., Clarke, S., Polly, P., Robertson, G. (2010). The alternatively spliced murine pregnane X receptor isoform, mPXRΔ171–211 exhibits a repressive action. The International Journal of Biochemistry and Cell Biology, 42(5), 672-682. [More Information]
  • Oh, B., Butow, P., Mullan, B., Beale, P., Pavlakis, N., Rosenthal, D., Clarke, S. (2010). The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. Asia-Pacific Journal of Clinical Oncology, 6(4), 342-349. [More Information]
  • Clarke, S. (2010). Updates in Medical Oncology. 2010 ARCS Australia Annual Scientific Congress.

2009

  • Matic, M., Nakhel, S., Lehnert, A., Polly, P., Clarke, S., Robertson, G. (2009). A novel approach to investigate the subcellular distribution of nuclear receptors in vivo. Nuclear Receptor Signaling, 7(-), 1-7. [More Information]
  • Chapuis, P., Bokey, E., Clarke, S., Beale, P., Dent, O. (2009). Adjuvant chemotherapy for stage C colonic cancer in a multidisciplinary setting. ANZ Journal of Surgery, 79(10), 685-692. [More Information]
  • Clarke, S. (2009). Advanced colorectal cancer - where are we going? AstraZeneca Challenges in Gastroenterology Symposium.
  • Chua, W., Peters, M., Loneragan, R., Clarke, S. (2009). Cetuximab-Associated Pulmonary Toxicity. Clinical Colorectal Cancer, 8(2), 118-120. [More Information]
  • Clarke, S. (2009). Chemotherapy and timing of surgery. Australia & New Zealand Medical & Surgical Gastrointestinal Week 2009.
  • Vardy, J., Dadasovich, R., Beale, P., Boyer, M., Clarke, S. (2009). Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC Cancer, 9(Article number 130), 130-1-130-6. [More Information]
  • Hong, P., Moore, M., McLachlan, A., Piquette-Miller, M., Xu, H., Clarke, S. (2009). Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opinion on Drug Metabolism and Toxicology, 5(3), 243-257. [More Information]
  • Sharma, R., Cunningham, D., Smith, P., Robertson, G., Dent, O., Clarke, S. (2009). Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients-analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. BMC Cancer, 9, 153-1-153-10. [More Information]
  • Clarke, S. (2009). Interactions with cancer therapies. Clinical Oncological Society of Australia 36th Annual Scientific Meeting: Awareness, Access, Action.
  • Clarke, S. (2009). Managing complex/multiple focus disease areas & networks: the cancer experience. National Institute of Complementary Medicine 2009 National Symposium: Supporting health priorities & industry growth.
  • Chua, W., Goldstein, D., Lee, C., Dhillon, H., Michael, M., Mitchell, P., Clark, S., Iacopetta, B. (2009). Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 101(6), 998-1004. [More Information]
  • Sobrero, A., Ackland, S., Clarke, S., Perez-Carrion, R., Chiara, S., Gapski, J., Mainwaring, P., Langer, B., Young, S. (2009). Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer. Oncology, 77(2), 113-119.
  • Clarke, S. (2009). Plasma proteomic predictors of response and toxicitv in colorectal cancer patients receiving chemotherapy. 2nd Sino-Australian Symposium, N/A: N/A.
  • Chua, W., Moore, M., Charles (nee Slaviero), K., Clarke, S. (2009). Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Current Opinion in Molecular Therapeutics, 11(6), 611-622. [More Information]
  • Clarke, S. (2009). Systemic therapy for Malignant Mesothelioma: An Overview. ANZAC Research Institute’s 8th Annual Symposium.
  • Chua, W., Moore, M., Beale, P., Clarke, S. (2009). Third-line Treatment Options for Metastatic Colorectal Cancer. Asia Pacific Journal of Oncology and Hematology, 1(1), 27-35.

2008

  • Van Cutsem, E., Verslype, C., Beale, P., Clarke, S., Bugat, R., Rakhit, A., Fettner, S., Brennscheidt, U., Feyereislova, A., Delord, J. (2008). A phase lb dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Annals of Oncology, 19(2), 332-339. [More Information]
  • Saltz, L., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T., Rivera, F., et al (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of Clinical Oncology, 26(12), 2013-2019. [More Information]
  • Read, J., Clarke, S. (2008). Clinical Nutrition. In E. Bruera, I. Higginson, C. Ripamonti, C. von Gunten (Eds.), Palliative Medicine, (pp. 595-601). United Kingdom: Hodder Arnold.
  • Clarke, S. (2008). DaVINCI Trial Update and Issues in 2nd line chemotherapy. 10th Annual Scientific Meeting of Australasian Gastro-Intestinal Trials Group.
  • Clarke, S. (2008). Differences in Chemotherapy. 1st Sino-Australian Symposium.
  • Sharma, R., Kacevska, M., London, R., Clarke, S., Liddle, C., Robertson, G. (2008). Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. British Journal of Cancer, 98(1), 91-97. [More Information]
  • Robertson, G., Liddle, C., Clarke, S. (2008). Inflammation and Altered Drug Clearance in Cancer: Transcriptional Repression of a Human CYP3A4 Transgene in Tumor-bearing Mice. Pharmacology and Therapeutics, 83(6), 894-897. [More Information]
  • Clarke, S. (2008). Inflammation and cancer drug metabolism. Sydney Cancer Conference 2008 (SCC2008), Sydney: University of Sydney.
  • Kacevska, M., Robertson, G., Clarke, S., Liddle, C. (2008). Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opinion on Drug Metabolism and Toxicology, 4(2), 137-149. [More Information]
  • Clarke, S. (2008). Inflammation, drug metabolism and chemotherapy toxicity. Hunter Medical Research Institute Conference on Translational Cancer Research.
  • Clarke, S. (2008). Inflammatory Response: An unrecognized source of variability in PK/PD of cancer chemotherapy. ASCPT 2008 Annual Meeting.
  • Clarke, S. (2008). Infusion vs bolus chemotherapy for colon cancer/Stage II Colon Cancer: Is adjuvant chemotherapy necessary? National Cancer Control Network 1st Asian Scientific Meeting.
  • Oh, B., Butow, P., Mullan, B., Clarke, S. (2008). Medical Qigong for cancer patients: Pilot study of impact on quality of life, side effects of treatment and inflammation. American Journal of Chinese Medicine, 36(3), 459-472. [More Information]
  • Clarke, S. (2008). New developments in the practice of lung cancer. The Oncology Forum of Chinese Physicians from China and the US (OFCCU).
  • Harrison, J., Solomon, M., Young, J., Meagher, A., Butow, P., Salkeld, G., Hruby, G., Clarke, S. (2008). Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. JAMA (formerly Archives Of Surgery), 143(4), 389-394. [More Information]
  • Haller, D., Cassidy, J., Clarke, S., Cunningham, D., Hoff, P., Rothenberg, M., Saltz, L., Allegra, C., et al (2008). Potential regional differences for the tolerability profiles of fluoropyrimidines. Journal of Clinical Oncology, 26(13), 2118-2123. [More Information]
  • Clarke, S. (2008). Predicting toxicity from chemotherapy. The Australian Health & Medical Research Congress 2008.
  • Cassidy, J., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T., Rivera, F., et al (2008). Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Journal of Clinical Oncology, 26(12), 2006-2012. [More Information]
  • Morgan, E., Goralski, K., Piquette-Miller, M., Renton, K., Robertson, G., Chaluvadi, M., Charles, K., Clarke, S., Kacevska, M., Liddle, C., et al (2008). Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metabolism and Disposition, 36(2), 205-216. [More Information]
  • Chua, W., Beale, P., Clarke, S., Leung, M. (2008). Retrospective review of mitomycin C use as third-line chemotherapy in metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 4(3), 132-136.
  • Zalcberg, J., Rosen, L., Abdi, E., Davis, I., Gutheil, J., Schnell, F., Cesano, A., Gayko, U., Chen, M., Clarke, S. (2008). Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer. Journal of Clinical Oncology, 26(8), 1386-1387. [More Information]
  • Sharma, R., Zucknick, M., London, R., Kacevska, M., Liddle, C., Clarke, S. (2008). Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clinical Colorectal Cancer, 7(5), 331-337. [More Information]
  • Sharma, R., Hoskins, J., Rivory, L., Zucknick, M., London, R., Liddle, C., Clarke, S. (2008). Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clinical Cancer Research, 14(3), 817-825. [More Information]

2007

  • Yeo, W., Boyer, M., Chung, H., Ong, S., Lim, R., Zee, B., Ma, B., Lam, K., Mo, F., Ng, E., Clarke, S., Beale, P., et al (2007). Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemotherapy and Pharmacology, 59(3), 295-300. [More Information]
  • Clarke, S., Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S. (2007). Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. Clinical Colorectal Cancer, 6(8), 578-582. [More Information]
  • Chuah, B., Lim, R., Boyer, M., Ong, A., Wong, S., Kong, H., Millward, M., Clarke, S., Goh, B. (2007). Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncologica, 46(2), 234-238. [More Information]
  • Li, K., Rivory, L., Clarke, S. (2007). Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules. British Journal of Cancer, 97(8), 1071-1076. [More Information]
  • Harrison, J., Solomon, M., Young, J., Meagher, A., Hruby, G., Salkeld, G., Clarke, S. (2007). Surgical and oncology trials for rectal cancer: Who will participate? Surgery, 142(1), 94-101. [More Information]
  • McKay, M., Sherman, J., Laver, M., Baker, M., Clarke, S., Molloy, M. (2007). The development of multiple reaction monitoring assays for liver-derived plasma proteins. Proteomics - Clinical Applications, 1(12), 1570-1581. [More Information]
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Tattersall, M., Goldstein, D. (2007). When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer. Journal of Clinical Oncology, 25(18S), 6509.

2006

  • Sharma, R., Rivory, L., Beale, P., Ong, S., Horvath, L., Clarke, S. (2006). A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. British Journal of Cancer, 94(7), 964-968. [More Information]
  • Tobin, P., Beale, P., Noney, L., Liddell, S., Rivory, L., Clarke, S. (2006). A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 57(3), 309-316. [More Information]
  • Mitchell, P., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Thomson, J., Clarke, S. (2006). Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clinical Colorectal Cancer, 6(2), 146-151. [More Information]
  • Nordman, I., Iyer, S., Joshua, A., Clarke, S. (2006). Advances in the adjuvant treatment of colorectal cancer. ANZ Journal of Surgery, 76(5), 373-380. [More Information]
  • Li, K., Rivory, L., Hoskins, J., Sharma, R., Clarke, S. (2006). Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. British Journal of Clinical Pharmacology, 63(1), 67-74. [More Information]
  • Read, J., Choy, S., Beale, P., Clarke, S. (2006). An evaluation of the prevalence of malnutrition in cancer patients attending the outpatient oncology clinic. Asia-Pacific Journal of Clinical Oncology, 2(2), 80-86.
  • Clarke, S., Sharma, R. (2006). Angiogenesis inhibitors in cancer - mechanisms of action. Australian Prescriber, 29(1), 9-12.
  • Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]
  • Sobrero, A., Ackland, S., Perez-Carrion, R., Chiara, S., Clarke, S., Giron, C., Langer, B., Zurlo, A., Young, S. (2006). Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer. 2006 American Society of Clinical Oncology (ASCO) Annual Meeting, United States: American Society of Clinical Oncology.
  • Read, J., Choy, S., Beale, P., Clarke, S. (2006). Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutrition and Cancer: an international journal, 55(1), 78-85. [More Information]
  • Read, J., Beale, P., Volker, D., Smith, N., Childs, A., Clarke, S. (2006). Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Supportive Care in Cancer, 15(3), 301-307. [More Information]
  • Rosen, L., Abdi, E., Davis, I., Gutheil, J., Schnell, F., Zalcberg, J., Cesano, A., Gayko, U., Chen, M., Clarke, S. (2006). Palifermin Reduces the Incidence of Oral Mucositis in Patients With Metastatic Colorectal Cancer Treated With Fluorouracil-Based Chemotherapy. Journal of Clinical Oncology, 24, 5194-5200. [More Information]
  • Aggarwal, G., Glare, P., Clarke, S., Chapuis, P. (2006). Palliative and shared care concepts in patients with advanced colorectal cancer. ANZ Journal of Surgery, 76(3), 175-180. [More Information]
  • Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
  • Michael, M., Goldstein, D., Clarke, S., Milner, A., Beale, P., Friedlander, M., Mitchell, P. (2006). Prognostic Factors Predictive of Response and Survival to a Modified FOLFOX Regimen: Importance of an Increased Neutrophil Count. Clinical Colorectal Cancer, 6(4), 297-304.
  • Michael, M., Thompson, M., Hicks, R., Mitchell, P., Ellis, A., Milner, A., Di Iulio, J., Scott, A., Gurtler, V., Clarke, S., Zalcberg, J., et al (2006). Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination. Journal of Clinical Oncology, 24(26), 4228-4235. [More Information]
  • Li, K., Rivory, L., Clarke, S. (2006). Solid-phase extraction (SPE) techniques for sample preparation in clinical and pharmaceutical analysis: A brief overview. Current Pharmaceutical Analysis, 2(2), 95-102.
  • Tobin, P., Clarke, S., Seale, J., Lee, S., Solomon, M., Aulds, S., Crawford, M., Gallagher, J., Eyers, T., Rivory, L. (2006). The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. British Journal of Clinical Pharmacology, 62(1), 122-129. [More Information]
  • Ackland, S., Clarke, S., Beale, P., Peters, G. (2006). Thymidylate synthase inhibitors. Update on Cancer Therapeutics, 1(4), 403-427.
  • Haller, D., Cassidy, J., Clarke, S., Cunningham, D., Van Cutsem, E., Hoff, P., Rothenberg, M., Saltz, L., Schmoll, H., Twelves, C. (2006). Tolerability of fluoropyrimidines appears to differ by region. 2006 ASCO Annual Meeting, United Kingdom: Oxford University Press.
  • Charles (nee Slaviero), K., Rivory, L., Brown, S., Liddle, C., Clarke, S., Robertson, G. (2006). Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clinical Cancer Research, 12(24), 7492-7497. [More Information]

2005

  • Clarke, S., Boyer, M., Millward, M., Underhill, C., Moylan, E., Yip, D., White, S., Childs, A., Beale, P., Latz, J., et al (2005). A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer, 49(3), 401-412. [More Information]
  • Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Clarke, S. (2005). Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. British Journal of Cancer, 92(5), 832-837. [More Information]
  • Sharpe, L., Butow, P., Smith, C., McConnell, D., Clarke, S. (2005). Changes in quality of life in patients with advanced cancer - Evidence of response shift and response restriction. Journal of Psychosomatic Research, 58(6), 497-504. [More Information]
  • Vardy, J., Clarke, S. (2005). Ewing''s sarcoma of the rectum: Are four cycles of chemotherapy enough? Reply. Journal of Clinical Oncology, 23(24), 5850-5850.
  • Sharma, R., Boyer, M., Clarke, S., Millward, M. (2005). Gefitinib in advanced non-small cell lung cancer. Internal Medicine Journal, 35(2), 77. [More Information]
  • Joshua, A., Cotroneo, A., Clarke, S. (2005). Humor and oncology. Journal of Clinical Oncology, 23(3), 645-648.
  • Read, J., Beale, P., Horvath, L., Volker, D., Childs, A., Smith, N., Clarke, S. (2005). Impact of fish-oil supplement on nutritional parameters, inflammation and chemotherapy induced toxicity in colorectal cancer (CRC) patients receiving FOLFIRI - A pilot study. Journal of Clinical Oncology, 23(16S (supplement)), Abstract 8243 S789-S789.
  • Sharma, R., Tobin, P., Clarke, S. (2005). Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncology, 6(2), 93-102. [More Information]
  • Read, J., Crockett, N., Volker, D., MacLennan, P., Choy, S., Beale, P., Clarke, S. (2005). Nutritional assessment in cancer: comparing the Mini-Nutritional Assessment (MNA) with the scored Patient-Generated Subjective Global Assessment (PGSGA). Nutrition and Cancer: an international journal, 53(1), 51-56. [More Information]
  • Li, K., Rivory, L., Clarke, S. (2005). Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 820(1), 121-30. [More Information]
  • Joshua, A., Adams, D., McKenzie, P., Solomon, M., Clarke, S. (2005). Small blue cell tumors of the rectum. Case 2. Small-cell carcinoma of the rectum. Journal of Clinical Oncology, 23(4), 912-3. [More Information]
  • Sharma, R., McLeod, D., Clarke, S. (2005). Small blue cell tumors of the rectum. Case 3. Atypical carcinoid of the rectum. Journal of Clinical Oncology, 23(4), 914-5. [More Information]
  • Vardy, J., Joshua, A., Clarke, S., Yarrow, P., Lin, B. (2005). Small blue cell tumors of the rectum: CASE 1. Ewing's sarcoma of the rectum. Journal of Clinical Oncology, 23(4), 910-912. [More Information]
  • Joshua, A., Adams, D., McKenzie, P., Solomon, M., Clarke, S. (2005). Small Blue Cell Tumors of the Rectum: CASE 2. Small-Cell Carcinoma of the Rectum. Journal of Clinical Oncology, 23(4), 912-913.
  • Sharma, R., McLeod, D., Clarke, S. (2005). Small Blue Cell Tumors of the Rectum: CASE 3. Atypical Carcinoid of the Rectum. Journal of Clinical Oncology, 23(4), 914-915.
  • Joshua, A., Boyer, M., Subramanian, R., Clarke, S. (2005). Smoking reduction does work: resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years. Respirology, 10(2), 233-238. [More Information]
  • Tobin, P., Seale, P., Lee, S., Solomon, M., Fields, S., Rivory, L., Clarke, S. (2005). The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. 2005 American Society of Clinical Oncology (ASCO) Annual Meeting, United States: American Society of Clinical Oncology.
  • Sharpe, L., Butow, P., Smith, C., McConnell, D., Clarke, S. (2005). The relationship between available support, unmet needs and caregiver burden in patients with advanced cancer and their carers. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 14(2), 102-114. [More Information]
  • Clarke, S., Boyer, M., Stockler, M., Venkatawaran, R., Nordman, I., Joshua, A. (2005). Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC). 2005 ASCO Annual Meeting, NY, USA: American Society of Clinical Oncology.
  • Joshua, A., Nordman, I., Venkataswaran, R., Clarke, S., Stockler, M., Boyer, M. (2005). Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Internal Medicine Journal, 35(8), 468-472. [More Information]

2004

  • Baker, S., Van Schaik, R., Rivory, L., Ten Tije, A., Dinh, K., Graveland, W., Schenk, P., Charles, J., Clarke, S., Carducci, M., Sparreboom, A., et al (2004). Factors Affecting Cytochrome P-450 3A Activity In Cancer Patients. Clinical Cancer Research, 10(12), 8341-8350.
  • Tobin, P., Rivory, L., Clarke, S. (2004). Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11). Pharmacology and Therapeutics, 76(5), 505-506.
  • Vardy, J., Engelhardt, K., Cox, K., Jacquet, J., McDade, A., Boyer, M., Beale, P., Clarke, S., Stockler, M., Loneragan, R., Waugh, R., Clarke, S. (2004). Long-Term Outcome Of Radiological-Guided Insertion Of Implanted Central Venous Access Port Devices (Cvapd) For The Delivery Of Chemotherapy In Cancer Patients: Institutional Experience And Review Of The Literature. British Journal of Cancer, 91(6), 1045-1049.
  • Blair, E., Rivory, L., Clarke, S., McLachlan, A. (2004). Population Pharmacokinetics Of Raltitrexed In Patients With Advanced Solid Tumours. British Journal of Clinical Pharmacology, 57(4), 416-426.
  • Charles (nee Slaviero), K., Clarke, S., McLachlan, A., Blair, E., Rivory, L. (2004). Population Pharmacokinetics Of Weekly Docetaxel In Patients With Advanced Cancer. British Journal of Clinical Pharmacology, 57(1), 44-53.
  • Zhang, M., Boyer, M., Rivory, L., Hong, A., Clarke, S., Stevens, G., Fife, K. (2004). Radiosensitization Of Vinorelbine And Gemcitabine In Nci-H460 Non-Small-Cell Lung Cancer Cells. International Journal of Radiation: Oncology - Biology - Physics, 58(2), 353-360. [More Information]
  • Featherstone, C., Clarke, S., Jackson, M., Shannon, K., McNeil, E., Tin, M., Clifford, A., O'Brien, C. (2004). Treatment Of Advanced Cancer Of The Larynx And Hypopharynx With Chemoradiation. ANZ Journal of Surgery, 74(7), 554-558.

2003

  • Smit, E., Mattson, K., von Pawel, J., Manegold, C., Clarke, S., Postmus, P. (2003). ALIMTA® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Annals of Oncology, 14(3), 455-460.
  • Clarke, S. (2003). An 85-year old woman with metastatic liver disease: clinical case review. Medicine Today, 4(1), 72-73.
  • Charles (nee Slaviero), K., Read, J., Clarke, S., Rivory, L. (2003). Baseline Nutritional Assessment in Advanced Cancer Patients Receiving Palliative Chemotherapy. Nutrition and Cancer: an international journal, 46(2), 148-157.
  • Tattersall, M., Clarke, S. (2003). Developments in drug delivery: implications for cancer care. Current Opinion in Oncology, 15(4), 293-299.
  • Van Der Wall, H., Clarke, S., Murray, I. (2003). Evaluation of primary bone tumours. In Peter J. Ell & Sanjiv Sam Gambhir (Eds.), Nuclear Medicine in Clinical Diagnosis and Treatment. 3rd ed, (pp. 623-639). Edinburgh: Churchill Livingstone.
  • Charles (nee Slaviero), K., Clarke, S., Rivory, L. (2003). Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncology, 4(4), 224-232.
  • Saw, R., Morgan, M., Koorey, D., Painter, D., Findlay, M., Stevens, G., Clarke, S., Chapuis, P., Solomon, M. (2003). P53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Diseases of the Colon and Rectum, 46(2), 192-202. [More Information]
  • Li, K., Clarke, S., Rivory, L. (2003). Quantitation of plasma thymidine by high-performance liquid chromatography - atmospheric pressure chemical ionization mass spectromentry and its application to pharmocodynamic studies in cancer patients. Analytica Chimica Acta, 486(1), 51-61.
  • Van Der Wall, H., Clarke, S., Murray, I. (2003). The evaluation of malignancy: metastatic bone disease. In Peter J. Ell & Sanjiv Sam Gambhir (Eds.), Nuclear Medicine in Clinical Diagnosis and Treatment. 3rd ed, (pp. 641-655). Edinburgh: Churchill Livingstone.
  • Tobin, P., Dodds, H., Clarke, S., Schnitzler, M., Rivory, L. (2003). The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours. Oncology reports, 10(6), 1977-1979.

2002

  • Aristides, M., Chen, J., Schulz, M., Williamson, E., Clarke, S., Grant, K. (2002). Conjoint analysis of a new chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced colorectal cancer. PharmacoEconomics, 20(11), 775-784.
  • Cunningham, D., Zalcberg, J., Maroun, J., James, R., Clarke, S., Maughan, T., Vincent, M., Schulz, J., Gonzalez Baron, M., Facchini, T. (2002). Efficacy, tolerability and management of raltitrexed (Tomudex TM) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials. European Journal of Cancer, 38(4), 478-486.
  • Rivory, L., Charles (nee Slaviero), K., Clarke, S. (2002). Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. British Journal of Cancer, 87(3), 277-280.
  • Vardy, J., Wong, E., Izard, M., Clifford, A., Clarke, S. (2002). Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review. Anti-Cancer Drugs, 13(3), 327-330.
  • Clarke, S. (2002). New treatments for advanced and metastatic colorectal cancer - clinical applications. Australian Prescriber, 25(5), 111-113.
  • Rischin, D., Ackland, S., Smith, J., Garg, M., Clarke, S., Millward, M., Toner, G., Zalcberg, J. (2002). Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies. Annals of Oncology, 13(11), 1810-1818.
  • Clarke, S., Abratt, R., Goedhals, L., Boyer, M., Millward, M., Ackland, S. (2002). Phase II trial of pemetrexed disodium (ALIMTA[R], LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Annals of Oncology, 13(5), 737-741.

2001

  • Rivory, L., Clarke, S., Boyer, M., Bishop, J. (2001). Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 765, 135-140.
  • Rivory, L., Charles (nee Slaviero), K., Hoskins, J., Clarke, S. (2001). The erythromycin breath test for the prediction of drug clearance. Clinical Pharmacokinetics, 40, 151-158.
  • Clarke, S., Bishop, J., Dodds, H., Rivory, L., Ong,, S. (2001). Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anti-Cancer Drugs, 12, 619-625.

2000

  • Clarke, S., Beale, P., Rivory, L. (2000). Clinical and preclinical pharmacokinetics of raltitrexed. Clinical Pharmacokinetics, 39, 429-443.

To update your profile click here. For support on your academic profile contact .